{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "27",
                "@timestamp": "2023-07-27T13:14:06.000006-04:00",
                "@year": "2023",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "06"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding-source-document": {
                "@source-document-type": "pii",
                "$": "S2059702923007676"
            },
            "xocs:funding-addon-generated-timestamp": "2023-05-18T02:55:32.015Z",
            "xocs:funding-text": "All costs relating to this consensus conference were covered by the ESMO from central dedicated funds (no grant number is applicable). There was no external funding of the event or the manuscript production.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60119956",
                            "@country": "kor",
                            "city": "Seoul",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Seoul National University Hospital"},
                                {"$": "Cancer Research Institute"},
                                {"$": "Seoul National University College of Medicine"},
                                {"$": "Seoul National University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60119956",
                                    "@dptid": "123181202"
                                },
                                {"@afid": "60013682"},
                                {"@afid": "60000656"},
                                {"@afid": "60021119"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-492a905f8e37f5dcfe3c33b0b8cf31d5-1",
                            "ce:source-text": "Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea",
                            "@dptid": "123181202"
                        },
                        "author": [
                            {
                                "preferred-name": {
                                    "ce:given-name": "S. A.",
                                    "ce:initials": "S.A.",
                                    "ce:surname": "Im",
                                    "ce:indexed-name": "Im S.A."
                                },
                                "@author-instance-id": "OB2BibRecID-948125942-d43958e4656b823569e48f69fe734d49-1",
                                "@seq": "1",
                                "ce:initials": "S.-A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Im",
                                "@auid": "34570185300",
                                "@orcid": "0000-0002-5396-6533",
                                "ce:indexed-name": "Im S.-A."
                            },
                            {
                                "preferred-name": {
                                    "ce:given-name": "K. H.",
                                    "ce:initials": "K.H.",
                                    "ce:surname": "Lee",
                                    "ce:indexed-name": "Lee K.H."
                                },
                                "@author-instance-id": "OB2BibRecID-948125942-cd03696dff6f48e9269aa6f3b5ab0901-1",
                                "@seq": "24",
                                "ce:initials": "K.-H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Lee",
                                "@auid": "55549466700",
                                "ce:indexed-name": "Lee K.-H."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Italy",
                            "@afid": "60003668",
                            "@country": "ita",
                            "city": "Novara",
                            "organization": [
                                {"$": "Department of Translational Medicine"},
                                {"$": "University Piemonte Orientale"}
                            ],
                            "affiliation-id": {
                                "@afid": "60003668",
                                "@dptid": "103235645"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-81cd9052e6380b0df276db891bd4d8e6-1",
                            "ce:source-text": "Department of Translational Medicine, University Piemonte Orientale, Novara, Italy",
                            "@dptid": "103235645"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "A.",
                                "ce:initials": "A.",
                                "ce:surname": "Gennari",
                                "ce:indexed-name": "Gennari A."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-a1a669996a6adc423bd3bb1c5ebcdb52-1",
                            "@seq": "2",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Gennari",
                            "@auid": "7003822754",
                            "ce:indexed-name": "Gennari A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60020857",
                            "@country": "kor",
                            "city": "Seoul",
                            "organization": [
                                {"$": "Division of Hematology-Oncology"},
                                {"$": "Department of Medicine"},
                                {"$": "Samsung Medical Center"},
                                {"$": "Sungkyunkwan University School of Medicine"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60020857",
                                    "@dptid": "112830784"
                                },
                                {"@afid": "60016329"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-65ba2443f8fd167e00d37b39808c7967-1",
                            "ce:source-text": "Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea",
                            "@dptid": "112830784"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "Y. H.",
                                "ce:initials": "Y.H.",
                                "ce:surname": "Park",
                                "ce:indexed-name": "Park Y.H."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-27d71724813b62fc00e7bd4d5c33b446-1",
                            "@seq": "3",
                            "ce:initials": "Y.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Park",
                            "@auid": "35273175600",
                            "ce:indexed-name": "Park Y.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60098516",
                            "@country": "kor",
                            "city": "Seoul",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Seoul National University Bundang Hospital"},
                                {"$": "Seoul National University College of Medicine"},
                                {"$": "Seoul National University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60098516",
                                    "@dptid": "110154308"
                                },
                                {"@afid": "60013682"},
                                {"@afid": "60000656"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-686a7aa6af49e46c20599a27efe7c143-1",
                            "ce:source-text": "Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea",
                            "@dptid": "110154308"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "J. H.",
                                "ce:initials": "J.H.",
                                "ce:surname": "Kim",
                                "ce:indexed-name": "Kim J.H."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-62f31d3b22e1783e40ee4f9150e0ac51-1",
                            "@seq": "4",
                            "ce:initials": "J.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kim",
                            "@auid": "57221538586",
                            "ce:indexed-name": "Kim J.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60069744",
                            "@country": "chn",
                            "city": "Beijing",
                            "organization": [
                                {"$": "Department of Oncology"},
                                {"$": "The Fifth Medical Center of PLA General Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60069744",
                                "@dptid": "113913180"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-e27f7f60a1778182b076f0bb98d5edb2-1",
                            "ce:source-text": "Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China",
                            "@dptid": "113913180"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "Z. F.",
                                "ce:initials": "Z.F.",
                                "ce:surname": "Jiang",
                                "ce:indexed-name": "Jiang Z.F."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-58cebb623d7ca405a0b2e61db44f0b96-1",
                            "@seq": "5",
                            "ce:initials": "Z.-F.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Jiang",
                            "@auid": "57205353572",
                            "ce:indexed-name": "Jiang Z.-F."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "India",
                            "@afid": "60079949",
                            "@country": "ind",
                            "city": "Mumbai",
                            "organization": {"$": "Tata Memorial Centre and Homi Bhabha National Institute"},
                            "affiliation-id": [
                                {"@afid": "60079949"},
                                {"@afid": "60018517"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-879ad06d7a84d5a7f51d963a7285f422-1",
                            "ce:source-text": "Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S.",
                                "ce:initials": "S.",
                                "ce:surname": "Gupta",
                                "ce:indexed-name": "Gupta S."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-19dcd18d9c102f7bf6f49a0faf9e7f61-1",
                            "@seq": "6",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Gupta",
                            "@auid": "57213338151",
                            "ce:indexed-name": "Gupta S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Indonesia",
                            "@afid": "60069388",
                            "@country": "idn",
                            "city": "Bandung",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Hasan Sadikin General Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60069388",
                                "@dptid": "112866591"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-80a1423aea4251407b734bd45fec1368-1",
                            "ce:source-text": "Department of Internal Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia",
                            "@dptid": "112866591"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "T. H.",
                                "ce:initials": "T.H.",
                                "ce:surname": "Fadjari",
                                "ce:indexed-name": "Fadjari T.H."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-28cee78ad61c6641fb0578c9189eb471-1",
                            "@seq": "7",
                            "ce:initials": "T.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Fadjari",
                            "@auid": "15055794000",
                            "ce:indexed-name": "Fadjari T.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Japan",
                            "@afid": "60160813",
                            "@country": "jpn",
                            "city": "Shimane",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "Shimane University Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60160813",
                                "@dptid": "126669038"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-d747794aead315472cfe759ef1ee834e-1",
                            "ce:source-text": "Department of Medical Oncology, Shimane University Hospital, Shimane, Japan",
                            "@dptid": "126669038"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "K.",
                                "ce:initials": "K.",
                                "ce:surname": "Tamura",
                                "ce:indexed-name": "Tamura K."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-f75893d4355d8484e813e74a02ccf54b-1",
                            "@seq": "8",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tamura",
                            "@auid": "58279482400",
                            "ce:indexed-name": "Tamura K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60010400",
                            "@country": "mys",
                            "city": "Kuala Lumpur",
                            "organization": [
                                {"$": "Cancer Centre"},
                                {"$": "Pantai Hospital Kuala Lumpur"}
                            ],
                            "affiliation-id": {
                                "@afid": "60010400",
                                "@dptid": "124435271"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-5173db2a630054dc25d6d629cad13df7-1",
                            "ce:source-text": "Cancer Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia",
                            "@dptid": "124435271"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "M. Y.",
                                "ce:initials": "M.Y.",
                                "ce:surname": "Mastura",
                                "ce:indexed-name": "Mastura M.Y."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-3428956cbca31010476f880259f84787-1",
                            "@seq": "9",
                            "ce:initials": "M.Y.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mastura",
                            "@auid": "14060650200",
                            "ce:indexed-name": "Mastura M.Y."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Philippines",
                            "@afid": "100624745",
                            "@country": "phl",
                            "city": "San Juan",
                            "organization": [
                                {"$": "Section of Medical Oncology"},
                                {"$": "Department of Internal Medicine"},
                                {"$": "Cardinal Santos Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "100624745",
                                "@dptid": "115786524"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-f4c45bb0321314df2edf5f9cccba753d-1",
                            "ce:source-text": "Section of Medical Oncology, Department of Internal Medicine, Cardinal Santos Cancer Center, San Juan, The Philippines",
                            "@dptid": "115786524"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "M. L.T.",
                                "ce:initials": "M.L.T.",
                                "ce:surname": "Abesamis-Tiambeng",
                                "ce:indexed-name": "Abesamis-Tiambeng M.L.T."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-f3a898a8901c7b91e6ab406842c9d04e-1",
                            "@seq": "10",
                            "ce:initials": "M.L.T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Abesamis-Tiambeng",
                            "@auid": "57192835193",
                            "ce:indexed-name": "Abesamis-Tiambeng M.L.T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Singapore",
                            "@afid": "60031809",
                            "@country": "sgp",
                            "city": "Singapore",
                            "organization": [
                                {"$": "Division of Medical Oncology"},
                                {"$": "National Cancer Centre Singapore"}
                            ],
                            "affiliation-id": {
                                "@afid": "60031809",
                                "@dptid": "104614771"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-9394e001566135e50be0f2ee39f1e81d-1",
                            "ce:source-text": "Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore",
                            "@dptid": "104614771"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "E. H.",
                                "ce:initials": "E.H.",
                                "ce:surname": "Lim",
                                "ce:indexed-name": "Lim E.H."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-139bf1091f65427940fa97e65a68c49e-1",
                            "@seq": "11",
                            "ce:initials": "E.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Lim",
                            "@auid": "57644559300",
                            "ce:indexed-name": "Lim E.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60073385",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "National Taiwan University Hospital"},
                                {"$": "Cancer Center Branch"}
                            ],
                            "affiliation-id": {
                                "@afid": "60073385",
                                "@dptid": "108334708"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-fce827744bb9c5043725c71ebbd95901-1",
                            "ce:source-text": "Department of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan",
                            "@dptid": "108334708"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "C. H.",
                                "ce:initials": "C.H.",
                                "ce:surname": "Lin",
                                "ce:indexed-name": "Lin C.H."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-768a0f27dfd65ccd3987ed403fb0b188-1",
                            "@seq": "12",
                            "ce:initials": "C.-H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Lin",
                            "@auid": "23668134300",
                            "ce:indexed-name": "Lin C.-H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60026046",
                            "@country": "tha",
                            "city": "Khon Kaen",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Khon Kaen University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60026046",
                                    "@dptid": "116192885"
                                },
                                {"@afid": "60017165"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-118cc3b2cdef41b24f287ef614c5542b-1",
                            "ce:source-text": "Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand",
                            "@dptid": "116192885"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "A.",
                                "ce:initials": "A.",
                                "ce:surname": "Sookprasert",
                                "ce:indexed-name": "Sookprasert A."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-bc43f89dfde8d9516d3646728813a36c-1",
                            "@seq": "13",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Sookprasert",
                            "@auid": "26024452800",
                            "ce:indexed-name": "Sookprasert A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Medical Oncology Unit"},
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "King Chulalongkorn Memorial Hospital and Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "129676101"
                                },
                                {"@afid": "60022183"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-6da73e70dfd4126167d930d31b3b8c82-1",
                            "ce:source-text": "Medical Oncology Unit, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "129676101"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "N.",
                                "ce:initials": "N.",
                                "ce:surname": "Parinyanitikul",
                                "ce:indexed-name": "Parinyanitikul N."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-255ebcae8f475ff76fce20fc4af6a1f5-1",
                            "@seq": "14",
                            "ce:initials": "N.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Parinyanitikul",
                            "@auid": "36554719100",
                            "ce:indexed-name": "Parinyanitikul N."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60013314",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": {"$": "Taipei-Veterans General Hospital"},
                            "affiliation-id": {"@afid": "60013314"},
                            "@affiliation-instance-id": "OB2BibRecID-948125942-99487397743a20d84de1f4c800ab39f0-1",
                            "ce:source-text": "Taipei-Veterans General Hospital, Taipei, Taiwan"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "L. M.",
                                "ce:initials": "L.M.",
                                "ce:surname": "Tseng",
                                "ce:indexed-name": "Tseng L.M."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-44af7eb52999a49b8f14f3e622d67c45-1",
                            "@seq": "15",
                            "ce:initials": "L.-M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tseng",
                            "@auid": "7201526690",
                            "ce:indexed-name": "Tseng L.-M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60069716",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": [
                                {"$": "School of Medicine"},
                                {"$": "National Yang Ming Chiao Tung University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60069716"},
                                {"@afid": "60199493"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-c79b6c917845f635e51eb9448ecf8172-1",
                            "ce:source-text": "School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "L. M.",
                                "ce:initials": "L.M.",
                                "ce:surname": "Tseng",
                                "ce:indexed-name": "Tseng L.M."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-44af7eb52999a49b8f14f3e622d67c45-1",
                            "@seq": "15",
                            "ce:initials": "L.-M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tseng",
                            "@auid": "7201526690",
                            "ce:indexed-name": "Tseng L.-M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Singapore",
                            "@afid": "127780700",
                            "@country": "sgp",
                            "city": "Singapore",
                            "organization": [
                                {"$": "Department of Haematology-Oncology"},
                                {"$": "National University Cancer Institute"},
                                {"$": "Singapore (NCIS)"}
                            ],
                            "affiliation-id": {
                                "@afid": "127780700",
                                "@dptid": "127781727"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-736ac54811c97f04229e55747e59a404-1",
                            "ce:source-text": "Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, Singapore",
                            "@dptid": "127781727"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S. C.",
                                "ce:initials": "S.C.",
                                "ce:surname": "Lee",
                                "ce:indexed-name": "Lee S.C."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-c6b405a8d5107cb0cc5f1e8aeb4be52e-1",
                            "@seq": "16",
                            "ce:initials": "S.-C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Lee",
                            "@auid": "56556623100",
                            "ce:indexed-name": "Lee S.-C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Philippines",
                            "@afid": "60071484",
                            "@country": "phl",
                            "organization": [
                                {"$": "The Cancer Institute of St Luke's Medical Center"},
                                {"$": "National Capital Region"}
                            ],
                            "affiliation-id": {
                                "@afid": "60071484",
                                "@dptid": "109694175"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-51e1486f1276829e898db05968b132e1-1",
                            "ce:source-text": "The Cancer Institute of St Luke's Medical Center, National Capital Region, The Philippines",
                            "@dptid": "109694175"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "P.",
                                "ce:initials": "P.",
                                "ce:surname": "Caguioa",
                                "ce:indexed-name": "Caguioa P."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-052cbaacfe89666c223c49617df3904e-1",
                            "@seq": "17",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Caguioa",
                            "@auid": "6506598676",
                            "ce:indexed-name": "Caguioa P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Philippines",
                            "@afid": "60071489",
                            "@country": "phl",
                            "organization": [
                                {"$": "The Cancer Institute of the University of Santo Tomas Hospital"},
                                {"$": "National Capital Region"}
                            ],
                            "affiliation-id": {"@afid": "60071489"},
                            "@affiliation-instance-id": "OB2BibRecID-948125942-12fb973fd1d8f8600b3b1b70cd50dbe5-1",
                            "ce:source-text": "The Cancer Institute of the University of Santo Tomas Hospital, National Capital Region, The Philippines"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "P.",
                                "ce:initials": "P.",
                                "ce:surname": "Caguioa",
                                "ce:indexed-name": "Caguioa P."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-052cbaacfe89666c223c49617df3904e-1",
                            "@seq": "17",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Caguioa",
                            "@auid": "6506598676",
                            "ce:indexed-name": "Caguioa P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60010400",
                            "@country": "mys",
                            "city": "Kuala Lumpur",
                            "organization": [
                                {"$": "Department of Radiotherapy"},
                                {"$": "Pantai Cancer Institute"},
                                {"$": "Pantai Hospital Kuala Lumpur"}
                            ],
                            "affiliation-id": {
                                "@afid": "60010400",
                                "@dptid": "106903677"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-a5480b71ee1514c26c87a4dbcf7ee6b8-1",
                            "ce:source-text": "Department of Radiotherapy, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia",
                            "@dptid": "106903677"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "M.",
                                "ce:initials": "M.",
                                "ce:surname": "Singh",
                                "ce:indexed-name": "Singh M."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-f4efb549ac5b6cac4762cc8f9a5633fa-1",
                            "@seq": "18",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Singh",
                            "@auid": "56591022100",
                            "ce:indexed-name": "Singh M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60010400",
                            "@country": "mys",
                            "city": "Kuala Lumpur",
                            "organization": [
                                {"$": "Department of Oncology"},
                                {"$": "Pantai Cancer Institute"},
                                {"$": "Pantai Hospital Kuala Lumpur"}
                            ],
                            "affiliation-id": {
                                "@afid": "60010400",
                                "@dptid": "127818242"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-a944e3bec6ddf3b0e9a531ca143e65a7-1",
                            "ce:source-text": "Department of Oncology, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia",
                            "@dptid": "127818242"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "M.",
                                "ce:initials": "M.",
                                "ce:surname": "Singh",
                                "ce:indexed-name": "Singh M."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-f4efb549ac5b6cac4762cc8f9a5633fa-1",
                            "@seq": "18",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Singh",
                            "@auid": "56591022100",
                            "ce:indexed-name": "Singh M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Japan",
                            "@afid": "60010925",
                            "@country": "jpn",
                            "city": "Kashiwa",
                            "organization": [
                                {"$": "Department of General Internal Medicine"},
                                {"$": "National Cancer Center Hospital East"}
                            ],
                            "affiliation-id": {
                                "@afid": "60010925",
                                "@dptid": "100270400"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-8157e92720d6f43404976e9083c753fa-1",
                            "ce:source-text": "Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan",
                            "@dptid": "100270400"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "Y.",
                                "ce:initials": "Y.",
                                "ce:surname": "Naito",
                                "ce:indexed-name": "Naito Y."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-ec6565907af430aa411d128f684f551d-1",
                            "@seq": "19",
                            "ce:initials": "Y.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Naito",
                            "@auid": "14025801500",
                            "ce:indexed-name": "Naito Y."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Indonesia",
                            "@afid": "60196808",
                            "@country": "idn",
                            "city": "Jakarta",
                            "organization": [
                                {"$": "Department of Hematology and Medical Oncology"},
                                {"$": "Dharmais Hospital (National Cancer Center)"}
                            ],
                            "affiliation-id": {
                                "@afid": "60196808",
                                "@dptid": "125648825"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-8b36cb1d4615169727ff98c4b6ec8ca9-1",
                            "ce:source-text": "Department of Hematology and Medical Oncology, Dharmais Hospital (National Cancer Center), Jakarta, Indonesia",
                            "@dptid": "125648825"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "R. A.",
                                "ce:initials": "R.A.",
                                "ce:surname": "Hukom",
                                "ce:indexed-name": "Hukom R.A."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-f92d0d3ae262b72ee836b0bdaf43b259-1",
                            "@seq": "20",
                            "ce:initials": "R.A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Hukom",
                            "@auid": "8977682700",
                            "ce:indexed-name": "Hukom R.A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "India",
                            "@afid": "60011172",
                            "@country": "ind",
                            "city": "Mumbai",
                            "organization": [
                                {"$": "Medical Oncology"},
                                {"$": "Lilavati Hospital and Research Centre and Bombay Hospital Institute of Medical Sciences"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60011172"},
                                {"@afid": "60079945"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-370b68f14238302a6a5f041be4cbb8c8-1",
                            "ce:source-text": "Medical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital Institute of Medical Sciences, Mumbai, India"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "B. K.",
                                "ce:initials": "B.K.",
                                "ce:surname": "Smruti",
                                "ce:indexed-name": "Smruti B.K."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-2fc8b438c394190deb5ea8444a66d27d-1",
                            "@seq": "21",
                            "ce:initials": "B.K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Smruti",
                            "@auid": "6506962894",
                            "ce:indexed-name": "Smruti B.K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60021182",
                            "@country": "chn",
                            "city": "Guangzhou",
                            "organization": [
                                {"$": "Cancer Center"},
                                {"$": "Sun Yat-sen University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60021182"},
                                {"@afid": "60082502"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-605b13b31855f6182d48f8a1e8bdd59e-1",
                            "ce:source-text": "Cancer Center, Sun Yat-sen University, Guangzhou, China"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S. S.",
                                "ce:initials": "S.S.",
                                "ce:surname": "Wang",
                                "ce:indexed-name": "Wang S.S."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-84aee5bda5c6834a348312b596293a0a-1",
                            "@seq": "22",
                            "ce:initials": "S.-S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wang",
                            "@auid": "57852636600",
                            "ce:indexed-name": "Wang S.-S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60068691",
                            "@country": "kor",
                            "city": "Seoul",
                            "organization": [
                                {"$": "Department of Oncology"},
                                {"$": "Asan Medical Centre"}
                            ],
                            "affiliation-id": {
                                "@afid": "60068691",
                                "@dptid": "113759348"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-cfbb5273ee512f4a0816970f5a6c65ed-1",
                            "ce:source-text": "Department of Oncology, Asan Medical Centre, Seoul, Republic of Korea",
                            "@dptid": "113759348"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S. B.",
                                "ce:initials": "S.B.",
                                "ce:surname": "Kim",
                                "ce:indexed-name": "Kim S.B."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-84cb9776d95d2c3da958918446ad9028-1",
                            "@seq": "23",
                            "ce:initials": "S.B.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kim",
                            "@auid": "34770722200",
                            "ce:indexed-name": "Kim S.B."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60199632",
                            "@country": "kor",
                            "city": "Incheon",
                            "organization": [
                                {"$": "Division of Medical Oncology"},
                                {"$": "Department of Internal Medicine"},
                                {"$": "Gachon University Gil Medical Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60199632",
                                "@dptid": "125763073"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-747396259064582661beb582274026d0-1",
                            "ce:source-text": "Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea",
                            "@dptid": "125763073"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "H. K.",
                                "ce:initials": "H.K.",
                                "ce:surname": "Ahn",
                                "ce:indexed-name": "Ahn H.K."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-14f038844b3020d9f6f5daae7d195505-1",
                            "@seq": "25",
                            "ce:initials": "H.K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Ahn",
                            "@auid": "50261094700",
                            "ce:indexed-name": "Ahn H.K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Switzerland",
                            "@afid": "60023561",
                            "@country": "che",
                            "city": "Lausanne",
                            "organization": [
                                {"$": "Oncology Department"},
                                {"$": "Lausanne University Hospital (CHUV)"}
                            ],
                            "affiliation-id": {
                                "@afid": "60023561",
                                "@dptid": "113497458"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-1024a1016b6ad9cc60cb6a8a9c17c216-1",
                            "ce:source-text": "Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland",
                            "@dptid": "113497458"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "S.",
                                "ce:initials": "S.",
                                "ce:surname": "Peters",
                                "ce:indexed-name": "Peters S."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-ba2c730707d6179a2a11fe6762355c1c-1",
                            "@seq": "26",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Peters",
                            "@auid": "57218315686",
                            "ce:indexed-name": "Peters S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "South Korea",
                            "@afid": "60068691",
                            "@country": "kor",
                            "city": "Seoul",
                            "organization": [
                                {"$": "Asan Medical Center"},
                                {"$": "University of Ulsan College of Medicine"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60068691"},
                                {"@afid": "60006240"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-948125942-d78f0ca82187a1194b4667c942cf7dcf-1",
                            "ce:source-text": "Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "T. W.",
                                "ce:initials": "T.W.",
                                "ce:surname": "Kim",
                                "ce:indexed-name": "Kim T.W."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-1ad1c38b300b53538186ee5ea6a33ff1-1",
                            "@seq": "27",
                            "ce:initials": "T.W.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kim",
                            "@auid": "56504151300",
                            "ce:indexed-name": "Kim T.W."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Japan",
                            "@afid": "60010925",
                            "@country": "jpn",
                            "city": "Kashiwa",
                            "organization": [
                                {"$": "Department of Gastroenterology and Gastrointestinal Oncology"},
                                {"$": "National Cancer Center Hospital East"}
                            ],
                            "affiliation-id": {
                                "@afid": "60010925",
                                "@dptid": "103589809"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-9193c52aa931b7436e017ef8a326179d-1",
                            "ce:source-text": "Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan",
                            "@dptid": "103589809"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "T.",
                                "ce:initials": "T.",
                                "ce:surname": "Yoshino",
                                "ce:indexed-name": "Yoshino T."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-62809cd7a736d5f1d8d055f3df3e9ce7-1",
                            "@seq": "28",
                            "ce:initials": "T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Yoshino",
                            "@auid": "57205400013",
                            "ce:indexed-name": "Yoshino T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Switzerland",
                            "@afid": "119221731",
                            "@country": "che",
                            "city": "Lugano",
                            "organization": {"$": "ESMO"},
                            "affiliation-id": {"@afid": "119221731"},
                            "@affiliation-instance-id": "OB2BibRecID-948125942-9310617c159378b2670b74493987d14b-1",
                            "ce:source-text": "ESMO, Lugano, Switzerland"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "G.",
                                "ce:initials": "G.",
                                "ce:surname": "Pentheroudakis",
                                "ce:indexed-name": "Pentheroudakis G."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-530e6da3e9220585ca9c9b8ae416c8ec-1",
                            "@seq": "29",
                            "ce:initials": "G.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Pentheroudakis",
                            "@auid": "56230606500",
                            "ce:indexed-name": "Pentheroudakis G."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Italy",
                            "@afid": "60030442",
                            "@country": "ita",
                            "city": "Milan",
                            "organization": [
                                {"$": "Istituto Europeo di Oncologia"},
                                {"$": "IRCCS"}
                            ],
                            "affiliation-id": {"@afid": "60030442"},
                            "@affiliation-instance-id": "OB2BibRecID-948125942-e8039983f8c0d71bf7f683784a7a5055-1",
                            "ce:source-text": "Istituto Europeo di Oncologia, IRCCS, Milan, Italy"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "G.",
                                "ce:initials": "G.",
                                "ce:surname": "Curigliano",
                                "ce:indexed-name": "Curigliano G."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-cce69c0c06a700b15ae82eaf719504e3-1",
                            "@seq": "30",
                            "ce:initials": "G.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Curigliano",
                            "@auid": "57221578995",
                            "ce:indexed-name": "Curigliano G."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Italy",
                            "@afid": "60030318",
                            "@country": "ita",
                            "city": "Milan",
                            "organization": [
                                {"$": "Department of Oncology and Haematology"},
                                {"$": "University of Milano"}
                            ],
                            "affiliation-id": {
                                "@afid": "60030318",
                                "@dptid": "109081535"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-be5a0bd3a73b43234bb4031317b14617-1",
                            "ce:source-text": "Department of Oncology and Haematology, University of Milano, Milan, Italy",
                            "@dptid": "109081535"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "G.",
                                "ce:initials": "G.",
                                "ce:surname": "Curigliano",
                                "ce:indexed-name": "Curigliano G."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-cce69c0c06a700b15ae82eaf719504e3-1",
                            "@seq": "30",
                            "ce:initials": "G.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Curigliano",
                            "@auid": "57221578995",
                            "ce:indexed-name": "Curigliano G."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Germany",
                            "@afid": "60000291",
                            "@country": "deu",
                            "city": "Munich",
                            "organization": [
                                {"$": "Breast Center"},
                                {"$": "Department of Obstetrics and Gynaecology and Comprehensive Cancer Center Munich"},
                                {"$": "LMU University Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60000291",
                                "@dptid": "113680458"
                            },
                            "@affiliation-instance-id": "OB2BibRecID-948125942-fe0aa455a008b084108a0d2cf28282e1-1",
                            "ce:source-text": "Breast Center, Department of Obstetrics and Gynaecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany",
                            "@dptid": "113680458"
                        },
                        "author": [{
                            "preferred-name": {
                                "ce:given-name": "N.",
                                "ce:initials": "N.",
                                "ce:surname": "Harbeck",
                                "ce:indexed-name": "Harbeck N."
                            },
                            "@author-instance-id": "OB2BibRecID-948125942-4e49ed0b08fc4bdd2265978be0044ac6-1",
                            "@seq": "31",
                            "ce:initials": "N.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Harbeck",
                            "@auid": "34570179900",
                            "ce:indexed-name": "Harbeck N."
                        }]
                    }
                ],
                "citation-title": "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer",
                "abstracts": "© 2023 The AuthorsThe most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.",
                "correspondence": {
                    "affiliation": {
                        "country": "South Korea",
                        "address-part": "101, Daehak-ro Jongno-gu",
                        "postal-code": "03080",
                        "@country": "kor",
                        "city": "Seoul",
                        "organization": [
                            {"$": "Department of Internal Medicine"},
                            {"$": "Seoul National University Hospital"},
                            {"$": "Cancer Research Institute"},
                            {"$": "Seoul National University College of Medicine"},
                            {"$": "Seoul National University"}
                        ],
                        "@affiliation-instance-id": "OB2BibRecID-948125942-81602e7f829b3e9b6bfbcc9e51c907e1-1"
                    },
                    "person": {
                        "@author-instance-id": "OB2BibRecID-948125942-d1bbdd552c124e5899892e2334e0604a-1",
                        "ce:initials": "S.-A.",
                        "ce:surname": "Im",
                        "ce:indexed-name": "Im S.-A."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "ESMO",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "guidelines",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "metastatic breast cancer",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Pan-Asian",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "treatment",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://www.journals.elsevier.com/esmo-open/",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "volisspag": {"voliss": {
                        "@volume": "8",
                        "@issue": "3"
                    }},
                    "@type": "j",
                    "sourcetitle": "ESMO Open",
                    "publicationdate": {
                        "month": "06",
                        "year": "2023",
                        "date-text": "June 2023",
                        "day": "01"
                    },
                    "sourcetitle-abbrev": "ESMO Open",
                    "@country": "gbr",
                    "issn": {
                        "$": "20597029",
                        "@type": "electronic"
                    },
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "Elsevier B.V."},
                    "article-number": "101541",
                    "@srcid": "21100873339"
                },
                "enhancement": {"classificationgroup": {"classifications": [
                    {
                        "@type": "EMCLASS",
                        "classification": [
                            {
                                "classification-code": "16",
                                "classification-description": "Cancer"
                            },
                            {
                                "classification-code": "17",
                                "classification-description": "Public Health, Social Medicine and Epidemiology"
                            },
                            {
                                "classification-code": "26",
                                "classification-description": "Immunology, Serology and Transplantation"
                            },
                            {
                                "classification-code": "37",
                                "classification-description": "Drug Literature Index"
                            }
                        ]
                    },
                    {
                        "@type": "ASJC",
                        "classification": [
                            {"$": "2730"},
                            {"$": "1306"}
                        ]
                    },
                    {
                        "@type": "SUBJABBR",
                        "classification": [
                            {"$": "MEDI"},
                            {"$": "BIOC"}
                        ]
                    }
                ]}},
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "The authors would like to thank the leaders of ESMO and KSMO for their support in facilitating this hybrid virtual/face-to-face meeting. They would also like to thank Ms K. Marinoni and Ms D. Young from the Scientific and Medical Division of ESMO, Ms Z. Othman from the ESMO Singapore Office and Ms Minhee Kim of KSMO for their assistance in the execution of the hybrid virtual/face-to-face meeting of experts together with Ms Rose Shin of the meeting agency, and the on-site IT team. Dr A. Kinsella of Cancer Communications and Consultancy Ltd, Cheshire, UK is acknowledged for her contribution to the preparation of the manuscript. Mrs N. Latino, ESMO Head of Scientific Affairs, is acknowledged for her contribution in the completion of the ESMO-MCBS table. All costs relating to this consensus conference were covered by the ESMO from central dedicated funds (no grant number is applicable). There was no external funding of the event or the manuscript production. MLTAT declares consulting fees and honoraria from MSD, Roche, Novartis, Eli Lilly and AstraZeneca. HKA declares consulting fees from Daiichi Sankyo, Amgen, Yuhan and Novartis, and honoraria from Roche, BMS, MSD, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Menarini, Eisai, Pfizer, Boryung Pharmaceutical Company, Celtrion, Pharmobio Korea Inc. and Yuhan. GC has served as consultant or advisor for Roche, Eli Lilly and BMS; served on a speaker's bureau for Roche, Pfizer and Eli Lilly; received travel funding from Pfizer and Roche; and received honoraria from Roche, Pfizer, Eli Lilly, Novartis, AstraZeneca and SeaGen, all outside the submitted work. THF declares honoraria from AstraZeneca Oncology Indonesia, Takeda Indonesia, Eisai Indonesia, Roche Oncology Indonesia, J & J Indonesia and Zueling Pharma Indonesia and role as head of division of Area Development for West Java, Indonesia for the Indonesian Society of Hematology and Medical Oncology. AG declares honoraria for advisory boards from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Novartis, Pfizer and Roche; honoraria for lectures from Eisai and Eli Lilly and honoraria for expert testimony from Gentili. SG declares honoraria from Lupin, Roche, Novartis, Eli Lilly, Eisai, Cipla, CADILA, Intas and AstraZeneca; honoraria for being on committees of the Indian Council of Medical Research (Government of India), Council of Scientific and Industrial Research (Government of India), Department of Biotechnology (Government of India), India Alliance and institutional; honoraria from Novartis and AstraZeneca for participation in steering committees; leadership roles include President of Indian Society of Medical and Paediatric Oncology and General Secretary of Women's Cancer Initiative - Tata Memorial Hospital, both roles unpaid. NH reports honoraria for lectures, advisory boards and/or personal fees from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz and SeaGen, and minority ownership interest in the West German Study Group. RAH declares honoraria from Roche, Novartis, MSD, Pfizer and Mylan, and support for attending meetings from Roche, MSD and Kalbe Pharma. SAI declares an institutional grant from AstraZeneca, Boryung Pharm, Daewoong Pharm, Eisai, Roche and Pfizer, and honoraria from AstraZeneca, Novartis, MSD, Roche, Pfizer; advisory role for AstraZeneca, Bertis, Daiichi Sankyo, Eisai, Hanmi, Lilly, MSD, Novartis, Roche and Pfizer. JHK declares an institutional grant from Ono Pharma Ltd. and honoraria from Novartis, MSD, Roche Pharma, Roche diagnostics, Pfizer, AstraZeneca, Eisai, Lilly, and Sanofi; fees for participation in data monitoring or advisory boards from Bixink, Eisai, Yuhan, Novartis, Daiichi Sankyo, Pfizer, Roche Pharma and Everest Medicines; institutional gifts from Eisai and Ono Pharma Ltd. SBK declares institutional funding from Novartis, Sanofi-Aventis and Dongkook Pharm Co.; consulting fees from Novartis, AstraZeneca, Lilly, DaeHwa Pharmaceutical Co Ltd. ISU Abxis, Beigene, OBI Pharma and Daiichi Sankyo; honoraria from Novartis, Pfizer, Lilly, OBI Pharma and Legochem Bioscience; participation on data safety monitoring or advisory boards for Novartis, AstraZeneca, MSD, Lilly and Daiichi Sankyo, and purchased stock in Genopeaks and Neogene TC. KHL declares honoraria from Pfizer, Novartis and Eli Lilly. SCL declares grants from Pfizer, Eisai, Taiho, ACT Genomics, MSD, Adagene and Epizyme; honoraria from Pfizer, Novartis, AstraZeneca, ACT Genomics, Eli Lilly, MSD and Roche and participation in data monitoring or advisory boards for Pfizer, Novartis, Eisai, Sanofi, Daiichi Sankyo, MSD and Roche. MYM declares institutional grants from MSD, Astella, Pfizer, Novartis, AstraZeneca, ARCUS, Amgen and honoraria from MSD, Amgen, Pfizer, Roche, Novartis, Zuelling Pharma, Specialised therapeutics, Eisai, GSK, Mundi Pharma, Eli Lilly and AstraZeneca. YN declares institutional grants from the Ministry of Health, Labour and Welfare, Abbvie, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, Bayer and honoraria from AstraZeneca, Eisai, Ono, Gardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, Fuji Film Toyama Chemistry, Taiho, Mundi, Bristol, Shionogi. NP declares honoraria from AstraZeneca, Eisai, Roche, Eli Lilly, Novartis, Pfizer and MSD. YHP declares grants from AstraZeneca, Pfizer, Novartis, Roche and Gencurix, consulting fees from AstraZeneca, Pfizer, Novartis, Roche, Eisai, Daiichi Sankyo, MSD and Lilly, honoraria from Pfizer, MSD, Novartis and Roche, and participation on data monitoring boards and advisory boards for Roche, Eisai, Daiichi Sankyo, AstraZeneca, MSD and Novartis. SP declares fees for consultancy/advisory roles from Abbvie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Bio Invent, Biocartis, Blueprint Medicines, Boehringer Ingelheim, BMS, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-star, Foundation Medicine, Genzyme, Gilhead, GSK, Illumina, Incyte, IQIVIA, iTHeos, Janssen, Medscape, MSD, Merck Serono, Mirati, Novartis, Novocure, Pharma Mar, Phosplatin Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, SeaGen, Takeda, Vaccibody, speaker roles for AstraZeneca, Boehringer Ingelheim, BMS, ecancer, Eli Lilly, Fishawack, Illumina, Imedex, Medscape, Mirati MSD, Novartis, OncologyEducation, PER, Pfizer, PRIME, RMEI, Roche/Genentech, RTP, Sanofi, Takeda and steering committee and trial chair roles as follows: AstraZeneca, coordinating PI, institutional, no financial interest, MERMAID-1; AstraZeneca, steering committee member, institutional, no financial interest, MERMAID-2, POSEIDON, MYSTIC; Beigene, steering committee member, institutional, no financial interest, BGB-A317-A1217-301/AdvanTIG-301; BMS, steering committee member, institutional, no financial interest, clinical trial steering committee CheckMate 743, CheckMate 73L, CheckMate 331 and 451; BMS, steering committee member, institutional, no financial interest, RELATIVITY 095; GSK, trial chair, institutional, no financial interest, clinical trial chair ZEAL-1; iTeos, steering committee member, institutional, no financial interest, Phase 2 Inupadenant with chemo; Mirati, steering committee member, institutional, no financial interest, clinical trial steering committee SAPPHIRE; MSD, steering committee member, institutional, no financial interest, clinical trial steering committee PEARLS, MK-7684A; Pharma Mar, steering committee member, institutional, no financial interest, LAGOON; Phosplatin Therapeutics, steering committee member, institutional, no financial interest, phase 1/2 trials; Roche/Genentech, trial chair, institutional, no financial interest, clinical trial chair Skyscraper-01; chair ALEX; steering committee BFAST; steering committee BEAT-Meso; steering committee ImPower-030, IMforte. Also role as ESMO president, ETOP/EORTC/SAKK PI, involved in academic trials, ETOP/IBCSG partners officer. Council member and scientific chair, SAKK, vice-President Lung Group, SAMO, Vice President. BKS declares honoraria from Novartis and Eli Lilly. MS declares honoraria from AstraZeneca, MSD, Accord Health and Novartis, support for attending meetings from the Malaysia Urology Association and roles as an ex-committee member of the Malaysian Oncological Society and chairman of the Annual Scientific congress of the Malaysian Oncological Society. KT declares grants from Pfizer, Daiichi Sankyo, Eli Lilly, AstraZeneca, Eisai; honoraria from Daiichi Sankyo, Eli Lilly, Chugai, MSD; and data monitoring or advisory board fees from Daiichi Sankyo. SSW declares a grant from Pfizer and honoraria from Pfizer, Roche, AstraZeneca, Novartis, Daiichi Sankyo, Eli Lilly, MSD and Henrui. TY declares institutional grants from Amgen, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Genomedia, MSD, Ono, Pfizer, Sanofi, Sysmex and Taiho, and honoraria Bayer, Chugai, Merck biopharma, MSD and Ono. All other authors have declared no conflicts of interest.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "26",
                    "@timestamp": "BST 03:33:34",
                    "@year": "2023",
                    "@month": "07"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2024435809",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "948125942",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20230446070",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "37178669",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20231337451",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20231781803",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "85159041839",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85159041839",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "641318789",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "911675116",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:pii": "S2059702923007676",
                    "ce:ern": "pii:S2059702923007676",
                    "ce:doi": "10.1016/j.esmoop.2023.101541"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "137",
                "reference": [
                    {
                        "ref-fulltext": "Sung, H., Ferlay, J., Siegel, R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:3 (2021), 209\u2013249.",
                        "@reference-instance-id": "OB2BibRecID-948125942-83af2e446e2877667cffdff36b682e23-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib1",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85100345654",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "71",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "209",
                                    "@last": "249"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Sung",
                                        "ce:indexed-name": "Sung H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ferlay",
                                        "ce:indexed-name": "Ferlay J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Siegel",
                                        "ce:indexed-name": "Siegel R.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "CA Cancer J Clin"
                        },
                        "ce:source-text": "Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249."
                    },
                    {
                        "ref-fulltext": "Anderson, W.F., Jatoi, I., Tse, J., et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:2 (2010), 232\u2013239.",
                        "@reference-instance-id": "OB2BibRecID-948125942-742477e081f75448fc74f68bd1e3e4bc-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Male breast cancer: a population-based comparison with female breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib2",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "74949102413",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "232",
                                    "@last": "239"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Anderson",
                                        "ce:indexed-name": "Anderson W.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Jatoi",
                                        "ce:indexed-name": "Jatoi I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Tse",
                                        "ce:indexed-name": "Tse J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Anderson WF, Jatoi I, Tse J, et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232-239."
                    },
                    {
                        "ref-fulltext": "Heer, E., Harper, A., Escandor, N., et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 8:8 (2020), e1027\u2013e1037.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b97b9c1d3cbde968116c742657488db9-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib3",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088143648",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "e1027",
                                    "@last": "e1037"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Heer",
                                        "ce:indexed-name": "Heer E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Harper",
                                        "ce:indexed-name": "Harper A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Escandor",
                                        "ce:indexed-name": "Escandor N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Glob Health"
                        },
                        "ce:source-text": "Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027-e1037."
                    },
                    {
                        "ref-fulltext": "Xu, S., Liu, Y., Zhang, T., et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Oncol, 11, 2021, 689562.",
                        "@reference-instance-id": "OB2BibRecID-948125942-ac6fd5f008335b9de66f3ad2ccf8529e-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib4",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "689562",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85107403355",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "11"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Oncol"
                        },
                        "ce:source-text": "Xu S, Liu Y, Zhang T, et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Oncol. 2021;11:689562."
                    },
                    {
                        "ref-fulltext": "Youn, H.J., Han, W., A review of the epidemiology of breast cancer in Asia: focus on risk factors. Asian Pac J Cancer Prev 21:4 (2020), 867\u2013880.",
                        "@reference-instance-id": "OB2BibRecID-948125942-7849a7dddff596874ffaf75380455e68-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "A review of the epidemiology of breast cancer in Asia: focus on risk factors"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib5",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084030308",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "867",
                                    "@last": "880"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Youn",
                                    "ce:indexed-name": "Youn H.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Han",
                                    "ce:indexed-name": "Han W."
                                }
                            ]},
                            "ref-sourcetitle": "Asian Pac J Cancer Prev"
                        },
                        "ce:source-text": "Youn HJ, Han W. A review of the epidemiology of breast cancer in Asia: focus on risk factors. Asian Pac J Cancer Prev. 2020;21(4):867-880."
                    },
                    {
                        "ref-fulltext": "Ginsburg, O., Bray, F., Coleman, M.P., et al. The global burden of women's cancers: a grand challenge in global health. Lancet 389:10071 (2017), 847\u2013860.",
                        "@reference-instance-id": "OB2BibRecID-948125942-ecf78e77a635ed075c397d1c92a7a6b3-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "The global burden of women's cancers: a grand challenge in global health"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib6",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85005916238",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "389",
                                    "@issue": "10071"
                                },
                                "pagerange": {
                                    "@first": "847",
                                    "@last": "860"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Ginsburg",
                                        "ce:indexed-name": "Ginsburg O."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Bray",
                                        "ce:indexed-name": "Bray F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Coleman",
                                        "ce:indexed-name": "Coleman M.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge in global health. Lancet. 2017;389(10071):847-860."
                    },
                    {
                        "ref-fulltext": "Malvia, S., Bagadi, S.A., Dubey, U.S., et al. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 13:4 (2017), 289\u2013295.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1ead8568d68c3b5bcdb9bd4f26e96305-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Epidemiology of breast cancer in Indian women"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib7",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85011949683",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "13",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "289",
                                    "@last": "295"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Malvia",
                                        "ce:indexed-name": "Malvia S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bagadi",
                                        "ce:indexed-name": "Bagadi S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "U.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Dubey",
                                        "ce:indexed-name": "Dubey U.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Asia Pac J Clin Oncol"
                        },
                        "ce:source-text": "Malvia S, Bagadi SA, Dubey US, et al. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-295."
                    },
                    {
                        "ref-fulltext": "Japanese cancer statistics by stage. Available at https://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2013.html. (Accessed 30 August 2022)",
                        "@reference-instance-id": "OB2BibRecID-948125942-1530ece42c5acca63481194904c10c20-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2013.html",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Japanese cancer statistics by stage"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib8",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165518063",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 30 August 2022)"
                        },
                        "ce:source-text": "Japanese cancer statistics by stage. Available at https://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2013.html. Accessed August 30, 2022."
                    },
                    {
                        "ref-fulltext": "Kang, S.Y., Lee, S.B., Kim, Y.S., et al. Breast cancer statistics in Korea, 2018. J Breast Cancer 24:2 (2021), 123\u2013137.",
                        "@reference-instance-id": "OB2BibRecID-948125942-85175e81d7f763919ad6a61a52464ad3-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Breast cancer statistics in Korea, 2018"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib9",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85105602216",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "123",
                                    "@last": "137"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Kang",
                                        "ce:indexed-name": "Kang S.Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee S.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim Y.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Breast Cancer"
                        },
                        "ce:source-text": "Kang SY, Lee SB, Kim YS, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer. 2021;24(2):123-137."
                    },
                    {
                        "ref-fulltext": "Bhoo-Pathy, N., Verkooijen, H.M., Tan, E.Y., et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting. Sci Rep, 5, 2015, 16252.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1069404c71700afa9575ddf5ddeb6274-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib10",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "16252",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "84946599591",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "5"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhoo-Pathy",
                                        "ce:indexed-name": "Bhoo-Pathy N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Verkooijen",
                                        "ce:indexed-name": "Verkooijen H.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Tan",
                                        "ce:indexed-name": "Tan E.Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Bhoo-Pathy N, Verkooijen HM, Tan EY, et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting. Sci Rep. 2015;5:16252."
                    },
                    {
                        "ref-fulltext": "Bhoo Pathy, N., Yip, C.H., Taib, N.A., et al. Breast cancer in multi-ethnic Asian setting: results from Singapore-Malaysia hospital based breast cancer registry. Breast 20 (2011), S75\u2013S80.",
                        "@reference-instance-id": "OB2BibRecID-948125942-c5a7f1c98829c59060762cc3938f89f5-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Breast cancer in multi-ethnic Asian setting: results from Singapore-Malaysia hospital based breast cancer registry"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib11",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79953063689",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "S75",
                                    "@last": "S80"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhoo Pathy",
                                        "ce:indexed-name": "Bhoo Pathy N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Yip",
                                        "ce:indexed-name": "Yip C.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Taib",
                                        "ce:indexed-name": "Taib N.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast"
                        },
                        "ce:source-text": "Bhoo Pathy N, Yip CH, Taib NA, et al. Breast cancer in multi-ethnic Asian setting: results from Singapore-Malaysia hospital based breast cancer registry. Breast. 2011;20:S75-S80."
                    },
                    {
                        "ref-fulltext": "Lin, C.H., Yap, Y.S., Lee, K.H., et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst 111:12 (2019), 1298\u20131306.",
                        "@reference-instance-id": "OB2BibRecID-948125942-6e8e610e9ad645fab36514f5256f0687-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib12",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068867455",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "111",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1298",
                                    "@last": "1306"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin C.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Yap",
                                        "ce:indexed-name": "Yap Y.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee K.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Natl Cancer Inst"
                        },
                        "ce:source-text": "Lin CH, Yap YS, Lee KH, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111(12):1298-1306."
                    },
                    {
                        "ref-fulltext": "Yap, Y.-S., Lu, Y.-S., Tamura, K., et al. Insights into breast cancer in the east versus the west: a review. JAMA Oncol 5:10 (2019), 1489\u20131496.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3d20d6391f3474f48e9582e248c96eeb-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Insights into breast cancer in the east versus the west: a review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib13",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065802784",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1489",
                                    "@last": "1496"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.-S.",
                                        "@_fa": "true",
                                        "ce:surname": "Yap",
                                        "ce:indexed-name": "Yap Y.-S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.-S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu Y.-S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Tamura",
                                        "ce:indexed-name": "Tamura K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Yap Y-S, Lu Y-S, Tamura K, et al. Insights into breast cancer in the east versus the west: a review. JAMA Oncol. 2019;5(10):1489-1496."
                    },
                    {
                        "ref-fulltext": "Hirko, K.A., Rocque, G., Reasor, E., et al. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med, 20(1), 2022, 72.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d8f9de1a3ef1faa8d239477e266b7a4c-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib14",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85124590613",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "72"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirko",
                                        "ce:indexed-name": "Hirko K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Rocque",
                                        "ce:indexed-name": "Rocque G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Reasor",
                                        "ce:indexed-name": "Reasor E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMC Med"
                        },
                        "ce:source-text": "Hirko KA, Rocque G, Reasor E, et al. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med. 2022;20(1):72."
                    },
                    {
                        "ref-fulltext": "Szostakowska, M., Trebinska-Stryjewska, A., Grybowska, E., et al. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat 173 (2019), 489\u2013497.",
                        "@reference-instance-id": "OB2BibRecID-948125942-882dc30a7c9583dd26b93d2034de0ba6-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib15",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85055961038",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "173"},
                                "pagerange": {
                                    "@first": "489",
                                    "@last": "497"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Szostakowska",
                                        "ce:indexed-name": "Szostakowska M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Trebinska-Stryjewska",
                                        "ce:indexed-name": "Trebinska-Stryjewska A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Grybowska",
                                        "ce:indexed-name": "Grybowska E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Szostakowska M, Trebinska-Stryjewska A, Grybowska E, et al. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173:489-497."
                    },
                    {
                        "ref-fulltext": "Shimoi, T., Nagai, S.E., Yoshinami, T., et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer 27:3 (2020), 322\u2013331.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0c87734459887bc53e87eae910e65863-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib16",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082927230",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "322",
                                    "@last": "331"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shimoi",
                                        "ce:indexed-name": "Shimoi T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Nagai",
                                        "ce:indexed-name": "Nagai S.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yoshinami",
                                        "ce:indexed-name": "Yoshinami T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer"
                        },
                        "ce:source-text": "Shimoi T, Nagai SE, Yoshinami T, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(3):322-331."
                    },
                    {
                        "ref-fulltext": "Uematsu, T., Nakashima, K., Kikuchi, M., et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 edition. Breast Cancer 27:1 (2020), 17\u201324.",
                        "@reference-instance-id": "OB2BibRecID-948125942-7f482d89df9ccb37599163473adf6730-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 edition"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib17",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077681154",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "17",
                                    "@last": "24"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Uematsu",
                                        "ce:indexed-name": "Uematsu T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Nakashima",
                                        "ce:indexed-name": "Nakashima K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kikuchi",
                                        "ce:indexed-name": "Kikuchi M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer"
                        },
                        "ce:source-text": "Uematsu T, Nakashima K, Kikuchi M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 edition. Breast Cancer. 2020;27(1):17-24."
                    },
                    {
                        "ref-fulltext": "Yeo, W., Ueno, T., Lin, C.H., et al. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat 177:3 (2019), 549\u2013559.",
                        "@reference-instance-id": "OB2BibRecID-948125942-875fffc2f9feb056f0190a5b4ff9e62e-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib18",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068851765",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "177",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "549",
                                    "@last": "559"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Yeo",
                                        "ce:indexed-name": "Yeo W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Ueno",
                                        "ce:indexed-name": "Ueno T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin C.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Yeo W, Ueno T, Lin CH, et al. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019;177(3):549-559."
                    },
                    {
                        "ref-fulltext": "Rangarao, R., Smruti, B.K., Singh, K., et al. Practical consensus recommendations on management of triple-negative metastatic breast cancer. South Asian J Cancer 7:2 (2018), 127\u2013131.",
                        "@reference-instance-id": "OB2BibRecID-948125942-671a340dce44ac93357840329efb301e-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Practical consensus recommendations on management of triple-negative metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib19",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097392939",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "127",
                                    "@last": "131"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Rangarao",
                                        "ce:indexed-name": "Rangarao R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Smruti",
                                        "ce:indexed-name": "Smruti B.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Singh",
                                        "ce:indexed-name": "Singh K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "South Asian J Cancer"
                        },
                        "ce:source-text": "Rangarao R, Smruti BK, Singh K, et al. Practical consensus recommendations on management of triple-negative metastatic breast cancer. South Asian J Cancer. 2018;7(2):127-131."
                    },
                    {
                        "ref-fulltext": "Korean Breast Cancer Society. The 9th Korean Clinical Practice Guideline for breast cancer 2021. Available at https://www.kbcs.or.kr/journal/file/211104_211102.pdf. (Accessed 3 May 2023)",
                        "@reference-instance-id": "OB2BibRecID-948125942-64481ae0d1359d0e5ed57c18f2a9af08-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.kbcs.or.kr/journal/file/211104_211102.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Korean Breast Cancer Society. The 9th Korean Clinical Practice Guideline for breast cancer 2021"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib20",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165520756",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available at (Accessed 3 May 2023)"
                        },
                        "ce:source-text": "Korean Breast Cancer Society. The 9th Korean Clinical Practice Guideline for breast cancer 2021. Available at https://www.kbcs.or.kr/journal/file/211104_211102.pdf."
                    },
                    {
                        "ref-fulltext": "Gennari, A., Andre, F., Barrios, C.H., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:12 (2021), 1475\u20131495.",
                        "@reference-instance-id": "OB2BibRecID-948125942-25c2dfd53db63a938ca9e1c88b9ce6fd-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib21",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85120812833",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1475",
                                    "@last": "1495"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gennari",
                                        "ce:indexed-name": "Gennari A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Andre",
                                        "ce:indexed-name": "Andre F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Barrios",
                                        "ce:indexed-name": "Barrios C.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Gennari A, Andre F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-1495."
                    },
                    {
                        "ref-fulltext": "Dykewicz CA, Centers for Disease Control and Prevention. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33:2 (2001), 139\u2013144.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a09ee958e63d5796afc1819803465e66-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2001"},
                            "ref-title": {"ref-titletext": "Dykewicz CA, Centers for Disease Control and Prevention. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib22",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0035879607",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "139",
                                    "@last": "144"
                                }
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Dykewicz CA, Centers for Disease Control and Prevention. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139-144."
                    },
                    {
                        "ref-fulltext": "Modi, S., Jascot, W., Yamashita, T., et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study. J Clin Oncol, 40, 2022 LBA3.",
                        "@reference-instance-id": "OB2BibRecID-948125942-c26a9d1f115f28f2baaffd53f5af9922-23",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib23",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85134004165",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "40"}},
                            "ref-text": "LBA3",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Jascot",
                                        "ce:indexed-name": "Jascot W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamashita",
                                        "ce:indexed-name": "Yamashita T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Modi S, Jascot W, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study. J Clin Oncol. 2022;40:LBA3."
                    },
                    {
                        "ref-fulltext": "https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-her2-testing-algorithms.pdf. (Accessed 3 May 2023)",
                        "@reference-instance-id": "OB2BibRecID-948125942-ca2c81f0467ac892667f717a2559f9bd-24",
                        "@id": "24",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-her2-testing-algorithms.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib24",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165517380",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 3 May 2023)"
                        },
                        "ce:source-text": "https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-her2-testing-algorithms.pdf"
                    },
                    {
                        "ref-fulltext": "Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 36:20 (2018), 2105\u20132122.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b4fccab4650e348c1a80fc62fd453602-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib25",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85049596746",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "2105",
                                    "@last": "2122"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Wolff",
                                        "ce:indexed-name": "Wolff A.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.E.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Hammond",
                                        "ce:indexed-name": "Hammond M.E.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Allison",
                                        "ce:indexed-name": "Allison K.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36(20):2105-2122."
                    },
                    {
                        "ref-fulltext": "Cardoso, F., Paluch-Shimon, S., Senkus, E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:12 (2020), 1623\u20131649.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d9d95f748626ac25d74dd16a6e5c978f-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib26",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094163853",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1623",
                                    "@last": "1649"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Cardoso",
                                        "ce:indexed-name": "Cardoso F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paluch-Shimon",
                                        "ce:indexed-name": "Paluch-Shimon S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Senkus",
                                        "ce:indexed-name": "Senkus E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649."
                    },
                    {
                        "ref-fulltext": "Lee, C.I., Gold, L.S., Nelson, H.D., et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast 24:1 (2015), 3\u201311.",
                        "@reference-instance-id": "OB2BibRecID-948125942-87bf2a666df84c92eda44449e4bc6749-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib27",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84920486555",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "3",
                                    "@last": "11"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee C.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gold",
                                        "ce:indexed-name": "Gold L.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Nelson",
                                        "ce:indexed-name": "Nelson H.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast"
                        },
                        "ce:source-text": "Lee CI, Gold LS, Nelson HD, et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2015;24(1):3-11."
                    },
                    {
                        "ref-fulltext": "Accordino, M.K., Wright, J.D., Vasan, S., et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol 34:24 (2016), 2820\u20132826.",
                        "@reference-instance-id": "OB2BibRecID-948125942-85a3d4d98b55920a5f2ef11f0a319121-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Use and costs of disease monitoring in women with metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib28",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84982121586",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "34",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "2820",
                                    "@last": "2826"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Accordino",
                                        "ce:indexed-name": "Accordino M.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wright",
                                        "ce:indexed-name": "Wright J.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Vasan",
                                        "ce:indexed-name": "Vasan S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Accordino MK, Wright JD, Vasan S, et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol. 2016;34(24):2820-2826."
                    },
                    {
                        "ref-fulltext": "Kosmin, M., Padhani, A.R., Gogbashian, A., et al. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297:3 (2020), 622\u2013629.",
                        "@reference-instance-id": "OB2BibRecID-948125942-8ee2853651e1e08c22fbd366cf743e41-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib29",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85096347642",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "297",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "622",
                                    "@last": "629"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kosmin",
                                        "ce:indexed-name": "Kosmin M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Padhani",
                                        "ce:indexed-name": "Padhani A.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gogbashian",
                                        "ce:indexed-name": "Gogbashian A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Radiology"
                        },
                        "ce:source-text": "Kosmin M, Padhani AR, Gogbashian A, et al. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology. 2020;297(3):622-629."
                    },
                    {
                        "ref-fulltext": "Fourney, D.R., Frangou, E.M., Ryken, T.C., et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:22 (2011), 3072\u20133077.",
                        "@reference-instance-id": "OB2BibRecID-948125942-2bd58a159a532c617dc2acc44a478ac3-30",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib30",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80051662170",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "3072",
                                    "@last": "3077"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Fourney",
                                        "ce:indexed-name": "Fourney D.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Frangou",
                                        "ce:indexed-name": "Frangou E.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Ryken",
                                        "ce:indexed-name": "Ryken T.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol. 2011;29(22):3072-3077."
                    },
                    {
                        "ref-fulltext": "Komorowski, A.S., Warner, E., MacKay, H.J., et al. Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening?. Clin Breast Cancer 20:1 (2020), e54\u2013e64.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d22e2b92fff9f33c9a4bfc28661d1e0b-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib31",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85071136687",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "e54",
                                    "@last": "e64"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Komorowski",
                                        "ce:indexed-name": "Komorowski A.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Warner",
                                        "ce:indexed-name": "Warner E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.J.",
                                        "@_fa": "true",
                                        "ce:surname": "MacKay",
                                        "ce:indexed-name": "MacKay H.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Breast Cancer"
                        },
                        "ce:source-text": "Komorowski AS, Warner E, MacKay HJ, et al. Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54-e64."
                    },
                    {
                        "ref-fulltext": "DeSantis, C.E., Ma, J., Gaudet, M.M., et al. Breast cancer statistics, 2019. CA Cancer J Clin 69:6 (2019), 438\u2013451.",
                        "@reference-instance-id": "OB2BibRecID-948125942-f118a94ee0445b4c47e1d6f0d4247155-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Breast cancer statistics, 2019"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib32",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073960571",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "69",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "438",
                                    "@last": "451"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeSantis",
                                        "ce:indexed-name": "DeSantis C.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gaudet",
                                        "ce:indexed-name": "Gaudet M.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "CA Cancer J Clin"
                        },
                        "ce:source-text": "DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438-451."
                    },
                    {
                        "ref-fulltext": "Goetz, M.P., Toi, M., Campone, M., et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:32 (2017), 3638\u20133646.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3e10c5df8e72781190d2b5efb57a415c-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "MONARCH 3: abemaciclib as initial therapy for advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib33",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85032984371",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "32"
                                },
                                "pagerange": {
                                    "@first": "3638",
                                    "@last": "3646"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Goetz",
                                        "ce:indexed-name": "Goetz M.P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Toi",
                                        "ce:indexed-name": "Toi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Campone",
                                        "ce:indexed-name": "Campone M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646."
                    },
                    {
                        "ref-fulltext": "Johnston, S., Martin, M., Di Leo, A., et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer, 5, 2019, 5.",
                        "@reference-instance-id": "OB2BibRecID-948125942-f0973a75dd5583abaa5a33ff981dca78-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib34",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85063207699",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {"@first": "5"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnston",
                                        "ce:indexed-name": "Johnston S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Leo",
                                        "ce:indexed-name": "Di Leo A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "NPJ Breast Cancer"
                        },
                        "ce:source-text": "Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5."
                    },
                    {
                        "ref-fulltext": "Johnston, S., O'Shaughnessy, J., Martin, M., et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer, 7(1), 2021, 80.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3aaf03d49c859e744bacb0eca3d4af1c-35",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib35",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85108336793",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "80"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnston",
                                        "ce:indexed-name": "Johnston S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "O'Shaughnessy",
                                        "ce:indexed-name": "O'Shaughnessy J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "NPJ Breast Cancer"
                        },
                        "ce:source-text": "Johnston S, O'Shaughnessy J, Martin M, et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7(1):80."
                    },
                    {
                        "ref-fulltext": "Finn, R.S., Rugo, H.S., Dieras, V.C., et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus palcebo plus letrozole (PBO + LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): analyses from PALOMA-2. J Clin Oncol, 40, 2022, LBA1003.",
                        "@reference-instance-id": "OB2BibRecID-948125942-ae6e5dfe4eadcac1d56408ece6055e3e-36",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus palcebo plus letrozole (PBO + LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): analyses from PALOMA-2"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib36",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85137230699",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "40"},
                                "pagerange": {"@first": "LBA1003"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Finn",
                                        "ce:indexed-name": "Finn R.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Dieras",
                                        "ce:indexed-name": "Dieras V.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus palcebo plus letrozole (PBO + LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): analyses from PALOMA-2. J Clin Oncol. 2022;40:LBA1003."
                    },
                    {
                        "ref-fulltext": "Im, S.A., Mukai, H., Park, I.H., et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 5 (2019), 1\u201319.",
                        "@reference-instance-id": "OB2BibRecID-948125942-7e93d29875789dba5e32ed60a5d0f887-37",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib37",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066946116",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "19"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Mukai",
                                        "ce:indexed-name": "Mukai H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park I.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Glob Oncol"
                        },
                        "ce:source-text": "Im SA, Mukai H, Park IH, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol. 2019;5:1-19."
                    },
                    {
                        "ref-fulltext": "Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:18 (2016), 1738\u20131748.",
                        "@reference-instance-id": "OB2BibRecID-948125942-ae198d5dab70070c5426fc8bd4c3abc2-38",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Ribociclib as first-line therapy for HR-positive, advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib38",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84994151988",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "375",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "1738",
                                    "@last": "1748"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Hortobagyi",
                                        "ce:indexed-name": "Hortobagyi G.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stemmer",
                                        "ce:indexed-name": "Stemmer S.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Burris",
                                        "ce:indexed-name": "Burris H.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748."
                    },
                    {
                        "ref-fulltext": "Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:7 (2018), 1541\u20131547.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a86a9fbebfbc7ac0323363c7d677fd30-39",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib39",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85050821270",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "1541",
                                    "@last": "1547"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Hortobagyi",
                                        "ce:indexed-name": "Hortobagyi G.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stemmer",
                                        "ce:indexed-name": "Stemmer S.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Burris",
                                        "ce:indexed-name": "Burris H.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-1547."
                    },
                    {
                        "ref-fulltext": "Im, S.A., Lu, Y.S., Bardia, A., et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:4 (2019), 307\u2013316.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3815718ec6fc28849d5d41ea8ab82102-40",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Overall survival with ribociclib plus endocrine therapy in breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib40",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068361995",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "381",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "307",
                                    "@last": "316"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu Y.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316."
                    },
                    {
                        "ref-fulltext": "Lu, Y.-S., Im, S.A., Colleoni, M., et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 28:5 (2022), 851\u2013859.",
                        "@reference-instance-id": "OB2BibRecID-948125942-da8e13e13528cfa9454f3ffa3151ee6b-41",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib41",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85125729661",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "851",
                                    "@last": "859"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.-S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu Y.-S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Colleoni",
                                        "ce:indexed-name": "Colleoni M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Lu Y-S, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851-859."
                    },
                    {
                        "ref-fulltext": "Tripathy, D., Im, S.A., Colleoni, M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19:7 (2018), 904\u2013915.",
                        "@reference-instance-id": "OB2BibRecID-948125942-76e00427c49000d9c56367136616c479-42",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib42",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047257394",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "904",
                                    "@last": "915"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Tripathy",
                                        "ce:indexed-name": "Tripathy D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Colleoni",
                                        "ce:indexed-name": "Colleoni M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915."
                    },
                    {
                        "ref-fulltext": "Lee, K.W.C., Lord, S., Finn, R.S., et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat 174:1 (2019), 271\u2013278.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b77a6ee926bf9f87dc9f7fd5649573f8-43",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib43",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85056886571",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "174",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "271",
                                    "@last": "278"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.W.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee K.W.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lord",
                                        "ce:indexed-name": "Lord S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Finn",
                                        "ce:indexed-name": "Finn R.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Lee KWC, Lord S, Finn RS, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;174(1):271-278."
                    },
                    {
                        "ref-fulltext": "Im, S.A., Yap, Y.S., Sohn, J., et al. Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET). Ann Oncol, 30, 2019, ix15 abstr 390.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1da855af0d8ed62f5ac5ea29465a6022-44",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib44",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088564926",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "30"},
                                "pagerange": {"@first": "ix15"}
                            },
                            "ref-text": "abstr 390",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Yap",
                                        "ce:indexed-name": "Yap Y.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Sohn",
                                        "ce:indexed-name": "Sohn J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Im SA, Yap YS, Sohn J, et al. Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET). Ann Oncol. 2019;30:ix15, abstr 390."
                    },
                    {
                        "ref-fulltext": "Sledge, G.W. Jr., Toi, M., Neven, P., et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:25 (2017), 2875\u20132884.",
                        "@reference-instance-id": "OB2BibRecID-948125942-052cf3a0ec4a4edc90b4f21edaae685c-45",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib45",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85027966887",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "25"
                                },
                                "pagerange": {
                                    "@first": "2875",
                                    "@last": "2884"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Sledge",
                                        "ce:suffix": "Jr.",
                                        "ce:indexed-name": "Sledge G.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Toi",
                                        "ce:indexed-name": "Toi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Neven",
                                        "ce:indexed-name": "Neven P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884."
                    },
                    {
                        "ref-fulltext": "Iwata, H., Im, S.A., Masuda, N., et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol 3:4 (2017), 289\u2013303.",
                        "@reference-instance-id": "OB2BibRecID-948125942-207c569fcf00d09733c30a2bebf4cc6d-46",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib46",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85020584632",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "289",
                                    "@last": "303"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Iwata",
                                        "ce:indexed-name": "Iwata H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Masuda",
                                        "ce:indexed-name": "Masuda N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Glob Oncol"
                        },
                        "ce:source-text": "Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol. 2017;3(4):289-303."
                    },
                    {
                        "ref-fulltext": "Cristofanilli, M., Turner, N.C., Bondarenko, I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:4 (2016), 425\u2013439.",
                        "@reference-instance-id": "OB2BibRecID-948125942-388c0ca67c2498b8a6eca10980ada51c-47",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib47",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84959316268",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "17",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "425",
                                    "@last": "439"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Cristofanilli",
                                        "ce:indexed-name": "Cristofanilli M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Turner",
                                        "ce:indexed-name": "Turner N.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Bondarenko",
                                        "ce:indexed-name": "Bondarenko I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439."
                    },
                    {
                        "ref-fulltext": "Slamon, D.J., Neven, P., Chia, S., et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:24 (2018), 2465\u20132472.",
                        "@reference-instance-id": "OB2BibRecID-948125942-ef9d9107c971145984821830945e4e5e-48",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib48",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85050815779",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "2465",
                                    "@last": "2472"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Slamon",
                                        "ce:indexed-name": "Slamon D.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Neven",
                                        "ce:indexed-name": "Neven P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Chia",
                                        "ce:indexed-name": "Chia S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472."
                    },
                    {
                        "ref-fulltext": "Goetz, M.P., Toi, M., Huober, J., et al. MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol, 33, 2022 LBA 15.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0c1a55308b8c258da2c724242d0032c5-49",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib49",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85140016057",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "33"}},
                            "ref-text": "LBA 15",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Goetz",
                                        "ce:indexed-name": "Goetz M.P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Toi",
                                        "ce:indexed-name": "Toi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Huober",
                                        "ce:indexed-name": "Huober J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Goetz MP, Toi M, Huober J, et al. MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol. 2022;33:LBA 15."
                    },
                    {
                        "ref-fulltext": "Inoue, K., Masuda, N., Iwata, H., et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer 28:5 (2021), 1038\u20131050.",
                        "@reference-instance-id": "OB2BibRecID-948125942-bcd616178d9c531ec13b411e4b1d7d76-50",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib50",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85103399365",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "1038",
                                    "@last": "1050"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Inoue",
                                        "ce:indexed-name": "Inoue K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Masuda",
                                        "ce:indexed-name": "Masuda N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Iwata",
                                        "ce:indexed-name": "Iwata H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer"
                        },
                        "ce:source-text": "Inoue K, Masuda N, Iwata H, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28(5):1038-1050."
                    },
                    {
                        "ref-fulltext": "Toi, M., Inoue, K., Masuda, N., et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci 112:6 (2021), 2381\u20132392.",
                        "@reference-instance-id": "OB2BibRecID-948125942-fe3f36b0d784214006daf77943849f42-51",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib51",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85104102846",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "112",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "2381",
                                    "@last": "2392"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Toi",
                                        "ce:indexed-name": "Toi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Inoue",
                                        "ce:indexed-name": "Inoue K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Masuda",
                                        "ce:indexed-name": "Masuda N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Sci"
                        },
                        "ce:source-text": "Toi M, Inoue K, Masuda N, et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci. 2021;112(6):2381-2392."
                    },
                    {
                        "ref-fulltext": "Turner, N.C., Slamon, D.J., Ro, J., et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:20 (2018), 1926\u20131936.",
                        "@reference-instance-id": "OB2BibRecID-948125942-2b4c8bf60c6f6fc5a3d2d2616b47d725-52",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Overall survival with palbociclib and fulvestrant in advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib52",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85056167513",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "379",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "1926",
                                    "@last": "1936"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Turner",
                                        "ce:indexed-name": "Turner N.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Slamon",
                                        "ce:indexed-name": "Slamon D.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ro",
                                        "ce:indexed-name": "Ro J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926-1936."
                    },
                    {
                        "ref-fulltext": "Sledge, G.W., Toi, M., Neven, P., et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:1 (2020), 116\u2013124.",
                        "@reference-instance-id": "OB2BibRecID-948125942-4cd65541b5c1869ebdeca9c6e9effe32-53",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib53",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072756648",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "116",
                                    "@last": "124"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Sledge",
                                        "ce:indexed-name": "Sledge G.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Toi",
                                        "ce:indexed-name": "Toi M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Neven",
                                        "ce:indexed-name": "Neven P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116-124."
                    },
                    {
                        "ref-fulltext": "Slamon, D.J., Neven, P., Chia, S., et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:6 (2020), 514\u2013524.",
                        "@reference-instance-id": "OB2BibRecID-948125942-021ced60e3ee492c6ded63739e6c245a-54",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Overall survival with ribociclib plus fulvestrant in advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib54",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85079075053",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "382",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "514",
                                    "@last": "524"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Slamon",
                                        "ce:indexed-name": "Slamon D.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Neven",
                                        "ce:indexed-name": "Neven P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Chia",
                                        "ce:indexed-name": "Chia S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-524."
                    },
                    {
                        "ref-fulltext": "Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386:10 (2022), 942\u2013950.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d67a6a32c6f6bb8d3efed0abbb14422b-55",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Overall survival with ribociclib plus letrozole in advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib55",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85126081055",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "942",
                                    "@last": "950"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Hortobagyi",
                                        "ce:indexed-name": "Hortobagyi G.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stemmer",
                                        "ce:indexed-name": "Stemmer S.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Burris",
                                        "ce:indexed-name": "Burris H.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950."
                    },
                    {
                        "ref-fulltext": "Park, Y.H., Kim, T.Y., Kim, G.M., et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 20:12 (2019), 1750\u20131759.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3e69bbbd19217c36946fbfc0f132700c-56",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib56",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075681308",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1750",
                                    "@last": "1759"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park Y.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim T.Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim G.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20(12):1750-1759."
                    },
                    {
                        "ref-fulltext": "Giuliano, M., Schettini, F., Rognoni, C., et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet 20:10 (2019), 1360\u20131369.",
                        "@reference-instance-id": "OB2BibRecID-948125942-de5354071b759a5c69563ba0c69c4255-57",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib57",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072661267",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1360",
                                    "@last": "1369"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Giuliano",
                                        "ce:indexed-name": "Giuliano M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Schettini",
                                        "ce:indexed-name": "Schettini F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Rognoni",
                                        "ce:indexed-name": "Rognoni C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet. 2019;20(10):1360-1369."
                    },
                    {
                        "ref-fulltext": "Lu YS, Mahidin E, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy. Paper presented at SABCS 2022. December 6-10, 2022. Abstract GS1-10.",
                        "@reference-instance-id": "OB2BibRecID-948125942-570d1617b8f19ddc723d6f8dac53ad04-58",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib58",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165516988",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy. Paper presented at SABCS 2022. December 6-10 Abstract GS1-10.",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu Y.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Mahidin",
                                        "ce:indexed-name": "Mahidin E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Azim",
                                        "ce:indexed-name": "Azim H."
                                    }
                                ],
                                "et-al": null
                            }
                        },
                        "ce:source-text": "Lu YS, Mahidin E, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy. Paper presented at SABCS 2022. December 6-10, 2022. Abstract GS1-10."
                    },
                    {
                        "ref-fulltext": "Klijn, J.G., Beex, L.V., Mauriac, L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:11 (2000), 903\u2013911.",
                        "@reference-instance-id": "OB2BibRecID-948125942-298260020832862cd626c0a58199796e-59",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2000"},
                            "ref-title": {"ref-titletext": "Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib59",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0034616656",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "92",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "903",
                                    "@last": "911"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Klijn",
                                        "ce:indexed-name": "Klijn J.G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Beex",
                                        "ce:indexed-name": "Beex L.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Mauriac",
                                        "ce:indexed-name": "Mauriac L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Natl Cancer Inst"
                        },
                        "ce:source-text": "Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92(11):903-911."
                    },
                    {
                        "ref-fulltext": "Kalinsky, K., Accordino, M.K., Chiuzan, C., et al. A randomized phase II trail of fulvestrant or examestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-neagtive metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol, 40, 2022 LBA 1004.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0a1b60322c4db46f93805017a13534cd-60",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "A randomized phase II trail of fulvestrant or examestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-neagtive metastatic breast cancer (MBC): MAINTAIN trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib60",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136456002",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "40"}},
                            "ref-text": "LBA 1004",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Kalinsky",
                                        "ce:indexed-name": "Kalinsky K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Accordino",
                                        "ce:indexed-name": "Accordino M.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chiuzan",
                                        "ce:indexed-name": "Chiuzan C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized phase II trail of fulvestrant or examestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-neagtive metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol. 2022;40:LBA 1004."
                    },
                    {
                        "ref-fulltext": "André, F., Ciruelos, E., Rubovszky, G., et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:20 (2019), 1929\u20131940.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1c51528a546fb6cfbc83fcda487b83f6-61",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib61",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065812556",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "1929",
                                    "@last": "1940"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "André",
                                        "ce:indexed-name": "Andre F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Ciruelos",
                                        "ce:indexed-name": "Ciruelos E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Rubovszky",
                                        "ce:indexed-name": "Rubovszky G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940."
                    },
                    {
                        "ref-fulltext": "André, F., Ciruelos, E.M., Juric, D., et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 32:2 (2021), 208\u2013217.",
                        "@reference-instance-id": "OB2BibRecID-948125942-be53ac824cf512885c30f63eb678bc54-62",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib62",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85098218091",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "208",
                                    "@last": "217"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "André",
                                        "ce:indexed-name": "Andre F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ciruelos",
                                        "ce:indexed-name": "Ciruelos E.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Juric",
                                        "ce:indexed-name": "Juric D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Andre F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208-217."
                    },
                    {
                        "ref-fulltext": "Rugo, H.S., Lerebours, F., Ciruelos, E., et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22:4 (2021), 489\u2013498.",
                        "@reference-instance-id": "OB2BibRecID-948125942-310a62c65652e6aa07dc64c0592f6ff0-63",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib63",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85103415098",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "489",
                                    "@last": "498"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lerebours",
                                        "ce:indexed-name": "Lerebours F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Ciruelos",
                                        "ce:indexed-name": "Ciruelos E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489-498."
                    },
                    {
                        "ref-fulltext": "Baselga, J., Campone, M., Piccart, M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:6 (2012), 520\u2013529.",
                        "@reference-instance-id": "OB2BibRecID-948125942-af5d77422d591894dd5e7911a0c6804b-64",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib64",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84863078767",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "366",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "520",
                                    "@last": "529"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Baselga",
                                        "ce:indexed-name": "Baselga J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Campone",
                                        "ce:indexed-name": "Campone M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Piccart",
                                        "ce:indexed-name": "Piccart M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529."
                    },
                    {
                        "ref-fulltext": "Cook, M.M., Al Rabadi, L., Kaempf, A.J., et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist 26:2 (2021), 101\u2013106.",
                        "@reference-instance-id": "OB2BibRecID-948125942-10032d7dce0774d4ee7c4d4dd9948f67-65",
                        "@id": "65",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib65",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097559327",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "101",
                                    "@last": "106"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Cook",
                                        "ce:indexed-name": "Cook M.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Al Rabadi",
                                        "ce:indexed-name": "Al Rabadi L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Kaempf",
                                        "ce:indexed-name": "Kaempf A.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncologist"
                        },
                        "ce:source-text": "Cook MM, Al Rabadi L, Kaempf AJ, et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist. 2021;26(2):101-106."
                    },
                    {
                        "ref-fulltext": "Jerusalem, G., de Boer, R.H., Hurvitz, S., et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol 4:10 (2018), 1367\u20131374.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5dd5e4b1dbc526d7f3f88451b0bd5fee-66",
                        "@id": "66",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib66",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051175969",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1367",
                                    "@last": "1374"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Jerusalem",
                                        "ce:indexed-name": "Jerusalem G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.H.",
                                        "@_fa": "true",
                                        "ce:surname": "de Boer",
                                        "ce:indexed-name": "de Boer R.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Hurvitz",
                                        "ce:indexed-name": "Hurvitz S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Jerusalem G, de Boer RH, Hurvitz S, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018;4(10):1367-1374."
                    },
                    {
                        "ref-fulltext": "Piccart, M., Hortobagyi, G.N., Campone, M., et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25:12 (2014), 2357\u20132362.",
                        "@reference-instance-id": "OB2BibRecID-948125942-2b2409c2220ed22d9520068056b5ec68-67",
                        "@id": "67",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib67",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84921807735",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2357",
                                    "@last": "2362"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Piccart",
                                        "ce:indexed-name": "Piccart M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Hortobagyi",
                                        "ce:indexed-name": "Hortobagyi G.N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Campone",
                                        "ce:indexed-name": "Campone M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357-2362."
                    },
                    {
                        "ref-fulltext": "Litton, J.K., Rugo, H.S., Ettl, J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:8 (2018), 753\u2013763.",
                        "@reference-instance-id": "OB2BibRecID-948125942-cae619fe567b983767d6b9a808a1c5f9-68",
                        "@id": "68",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib68",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052504313",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "379",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "753",
                                    "@last": "763"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Litton",
                                        "ce:indexed-name": "Litton J.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ettl",
                                        "ce:indexed-name": "Ettl J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763."
                    },
                    {
                        "ref-fulltext": "Robson, M., Goessl, C., Domchek, S., Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med 377:18 (2017), 1792\u20131793.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0d0fbe483434fedf8fd7f7aa38fd0859-69",
                        "@id": "69",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Olaparib for metastatic germline BRCA-mutated breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib69",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85032738037",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "377",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "1792",
                                    "@last": "1793"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Robson",
                                    "ce:indexed-name": "Robson M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Goessl",
                                    "ce:indexed-name": "Goessl C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Domchek",
                                    "ce:indexed-name": "Domchek S."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Robson M, Goessl C, Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med. 2017;377(18):1792-1793."
                    },
                    {
                        "ref-fulltext": "Brufsky, A.M., Hurvitz, S., Perez, E., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:32 (2011), 4286\u20134293.",
                        "@reference-instance-id": "OB2BibRecID-948125942-451428cfe12004b8482cb84e4db43f58-70",
                        "@id": "70",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib70",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "81155123190",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "32"
                                },
                                "pagerange": {
                                    "@first": "4286",
                                    "@last": "4293"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Brufsky",
                                        "ce:indexed-name": "Brufsky A.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Hurvitz",
                                        "ce:indexed-name": "Hurvitz S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Perez",
                                        "ce:indexed-name": "Perez E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286-4293."
                    },
                    {
                        "ref-fulltext": "Kanai, M., Kawaguchi, T., Kotaka, M., et al. Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population. Ann Oncol, 31, 2020, s1359.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0f45e53c49597ef79bf052a0488994ca-71",
                        "@id": "71",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib71",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85114677478",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "31"},
                                "pagerange": {"@first": "s1359"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kanai",
                                        "ce:indexed-name": "Kanai M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Kawaguchi",
                                        "ce:indexed-name": "Kawaguchi T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kotaka",
                                        "ce:indexed-name": "Kotaka M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Kanai M, Kawaguchi T, Kotaka M, et al. Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population. Ann Oncol. 2020;31:s1359."
                    },
                    {
                        "ref-fulltext": "Gennari, A., Stockler, M., Puntoni, M., et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:16 (2011), 2144\u20132149.",
                        "@reference-instance-id": "OB2BibRecID-948125942-71001e0d96231d251ab0c071d050e9ee-72",
                        "@id": "72",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib72",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79957936823",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "2144",
                                    "@last": "2149"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gennari",
                                        "ce:indexed-name": "Gennari A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stockler",
                                        "ce:indexed-name": "Stockler M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Puntoni",
                                        "ce:indexed-name": "Puntoni M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144-2149."
                    },
                    {
                        "ref-fulltext": "Park, Y.H., Jung, K.H., Im, S.A., et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 31:14 (2013), 1732\u20131739.",
                        "@reference-instance-id": "OB2BibRecID-948125942-37f32d6a51c6ce0f5e6e22400d412128-73",
                        "@id": "73",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib73",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84879476708",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "1732",
                                    "@last": "1739"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park Y.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Jung",
                                        "ce:indexed-name": "Jung K.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Park YH, Jung KH, Im SA, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013;31(14):1732-1739."
                    },
                    {
                        "ref-fulltext": "Rugo, H.S., Bardia, A., Marme, F., et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 40:29 (2022), 3365\u20133376.",
                        "@reference-instance-id": "OB2BibRecID-948125942-08f96cdc7f5082e1938f7dde2fe07073-74",
                        "@id": "74",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib74",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85139572298",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "40",
                                    "@issue": "29"
                                },
                                "pagerange": {
                                    "@first": "3365",
                                    "@last": "3376"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Marme",
                                        "ce:indexed-name": "Marme F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022; 40(29):3365-3376."
                    },
                    {
                        "ref-fulltext": "Rugo, H.S., Bardia, A., Marme, F., et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol, 33, 2022, S1386.",
                        "@reference-instance-id": "OB2BibRecID-948125942-460330b01e909d82e7d547f14b319b58-75",
                        "@id": "75",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib75",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85140016057",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "33"},
                                "pagerange": {"@first": "S1386"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Marme",
                                        "ce:indexed-name": "Marme F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Rugo HS, Bardia A, Marme F, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol. 2022;33:S1386."
                    },
                    {
                        "ref-fulltext": "Kaklamani V, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: updated results by duration of prior CDK4/6 inhibitor in metastatic setting. Paper presented at 2022 San Antonio Breast Cancer Symposium. December 8, 2022. Abstract GS3-01.",
                        "@reference-instance-id": "OB2BibRecID-948125942-06d7081e78593f79fe64904eace5356a-76",
                        "@id": "76",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib76",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165520999",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: updated results by duration of prior CDK4/6 inhibitor in metastatic setting. Paper presented at 2022 San Antonio Breast Cancer Symposium. December 8 Abstract GS3-01.",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Kaklamani",
                                        "ce:indexed-name": "Kaklamani V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Bidard",
                                        "ce:indexed-name": "Bidard F.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Neven",
                                        "ce:indexed-name": "Neven P."
                                    }
                                ],
                                "et-al": null
                            }
                        },
                        "ce:source-text": "Kaklamani V, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: updated results by duration of prior CDK4/6 inhibitor in metastatic setting. Paper presented at 2022 San Antonio Breast Cancer Symposium. December 8, 2022. Abstract GS3-01."
                    },
                    {
                        "ref-fulltext": "Baselga, J., Cortes, J., Kim, S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:2 (2012), 109\u2013119.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5e1abe0d6bccb7981c335ed1c6f8a637-77",
                        "@id": "77",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib77",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84862914692",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "366",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "109",
                                    "@last": "119"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Baselga",
                                        "ce:indexed-name": "Baselga J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cortes",
                                        "ce:indexed-name": "Cortes J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119."
                    },
                    {
                        "ref-fulltext": "Swain, S.M., Miles, D., Kim, S.B., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:4 (2020), 519\u2013530.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b61537ebc98db9bed43acd22721ef32e-78",
                        "@id": "78",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib78",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082497684",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "519",
                                    "@last": "530"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Swain",
                                        "ce:indexed-name": "Swain S.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Miles",
                                        "ce:indexed-name": "Miles D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-530."
                    },
                    {
                        "ref-fulltext": "Rimawi, M., Ferrero, J.M., de la Haba-Rodriguez, J., et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36:28 (2018), 2826\u20132835.",
                        "@reference-instance-id": "OB2BibRecID-948125942-6a02fe3d0c5c679c872a3e2a53797f01-79",
                        "@id": "79",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib79",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85054148622",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "28"
                                },
                                "pagerange": {
                                    "@first": "2826",
                                    "@last": "2835"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Rimawi",
                                        "ce:indexed-name": "Rimawi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ferrero",
                                        "ce:indexed-name": "Ferrero J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "de la Haba-Rodriguez",
                                        "ce:indexed-name": "de la Haba-Rodriguez J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826-2835."
                    },
                    {
                        "ref-fulltext": "Cortés, J., Fumoleau, P., Bianchi, G.V., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:14 (2012), 1594\u20131600.",
                        "@reference-instance-id": "OB2BibRecID-948125942-9147592befe05bab7d1b8160cb001957-80",
                        "@id": "80",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib80",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84862894846",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "1594",
                                    "@last": "1600"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cortés",
                                        "ce:indexed-name": "Cortes J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Fumoleau",
                                        "ce:indexed-name": "Fumoleau P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Bianchi",
                                        "ce:indexed-name": "Bianchi G.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594-1600."
                    },
                    {
                        "ref-fulltext": "Kaufman, B., Mackey, J.R., Clemens, M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:33 (2009), 5529\u20135537.",
                        "@reference-instance-id": "OB2BibRecID-948125942-2ffcb2997f766ba1c75995b489d2dd59-81",
                        "@id": "81",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib81",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "73949105921",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "33"
                                },
                                "pagerange": {
                                    "@first": "5529",
                                    "@last": "5537"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kaufman",
                                        "ce:indexed-name": "Kaufman B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Mackey",
                                        "ce:indexed-name": "Mackey J.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Clemens",
                                        "ce:indexed-name": "Clemens M.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529-5537."
                    },
                    {
                        "ref-fulltext": "Yuan, Z., Huang, J.-J., Hua, X., et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: the SYSUCC-002 randomized clinical trial. J Clin Oncol, 39(suppl 15), 2021, 1003.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b6ef77004ed639877a61238eb8cb56dd-82",
                        "@id": "82",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: the SYSUCC-002 randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib82",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85158872281",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "39"},
                                "pagerange": {"@first": "1003"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Yuan",
                                        "ce:indexed-name": "Yuan Z."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.-J.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang J.-J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Hua",
                                        "ce:indexed-name": "Hua X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Yuan Z, Huang J-J, Hua X, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: the SYSUCC-002 randomized clinical trial. J Clin Oncol. 2021;39(suppl 15):1003."
                    },
                    {
                        "ref-fulltext": "Johnston, S.R.D., Hegg, R., Im, S.A., et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol 36:8 (2018), 741\u2013748.",
                        "@reference-instance-id": "OB2BibRecID-948125942-9c694be19f51189a170ca8900667ed2c-83",
                        "@id": "83",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib83",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85043390280",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "741",
                                    "@last": "748"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.R.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnston",
                                        "ce:indexed-name": "Johnston S.R.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Hegg",
                                        "ce:indexed-name": "Hegg R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 2018;36(8):741-748."
                    },
                    {
                        "ref-fulltext": "Johnston, S., Pippen, J. Jr., Pivot, X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:33 (2009), 5538\u20135546.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5a3fefa08dbf38137b8ee51abe2c1a2c-84",
                        "@id": "84",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib84",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "73149115341",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "33"
                                },
                                "pagerange": {
                                    "@first": "5538",
                                    "@last": "5546"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Johnston",
                                        "ce:indexed-name": "Johnston S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Pippen",
                                        "ce:suffix": "Jr.",
                                        "ce:indexed-name": "Pippen J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Pivot",
                                        "ce:indexed-name": "Pivot X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538-5546."
                    },
                    {
                        "ref-fulltext": "Cortes, J., Kim, S.B., Chung, W.P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386:12 (2022), 1143\u20131154.",
                        "@reference-instance-id": "OB2BibRecID-948125942-abe8f5d2a97ad7589de1bc35f16642f3-85",
                        "@id": "85",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib85",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85127402448",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "386",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1143",
                                    "@last": "1154"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cortes",
                                        "ce:indexed-name": "Cortes J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Chung",
                                        "ce:indexed-name": "Chung W.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143-1154."
                    },
                    {
                        "ref-fulltext": "Lin, N.U., Borges, V., Anders, C., et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 38:23 (2020), 2610\u20132619.",
                        "@reference-instance-id": "OB2BibRecID-948125942-b6bacb8d2cfbd4303bb1bbf18d8306e9-86",
                        "@id": "86",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib86",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086111080",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "2610",
                                    "@last": "2619"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.U.",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin N.U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Borges",
                                        "ce:indexed-name": "Borges V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Anders",
                                        "ce:indexed-name": "Anders C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610-2619."
                    },
                    {
                        "ref-fulltext": "Murthy, R.K., Loi, S., Okines, A., et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382:7 (2020), 597\u2013609.",
                        "@reference-instance-id": "OB2BibRecID-948125942-4300209ef634d8234dd6712f489465cc-87",
                        "@id": "87",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib87",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077435898",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "382",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "597",
                                    "@last": "609"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Murthy",
                                        "ce:indexed-name": "Murthy R.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Loi",
                                        "ce:indexed-name": "Loi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Okines",
                                        "ce:indexed-name": "Okines A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609."
                    },
                    {
                        "ref-fulltext": "Modi, S., Saura, C., Yamashita, T., et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Cancer Res 81:suppl 4 (2021), PD3\u2013PD06.",
                        "@reference-instance-id": "OB2BibRecID-948125942-62664bf612b4b5b9a1175a1e8fad296a-88",
                        "@id": "88",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib88",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85107458632",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "81"},
                                "pagerange": {
                                    "@first": "PD3",
                                    "@last": "PD06"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Saura",
                                        "ce:indexed-name": "Saura C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamashita",
                                        "ce:indexed-name": "Yamashita T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Res"
                        },
                        "ce:source-text": "Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Cancer Res. 2021;81(suppl 4):PD3-06."
                    },
                    {
                        "ref-fulltext": "Verma, S., Miles, D., Gianni, L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:19 (2012), 1783\u20131791.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1db79819730b285ac6e404e05f8b49a7-89",
                        "@id": "89",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Trastuzumab emtansine for HER2-positive advanced breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib89",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84868520609",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "367",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "1783",
                                    "@last": "1791"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Verma",
                                        "ce:indexed-name": "Verma S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Miles",
                                        "ce:indexed-name": "Miles D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gianni",
                                        "ce:indexed-name": "Gianni L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791."
                    },
                    {
                        "ref-fulltext": "Blackwell, K.L., Burstein, H.J., Storniolo, A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:7 (2010), 1124\u20131130.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a35ae78934854b22e460a02a27c09625-90",
                        "@id": "90",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib90",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77949884661",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "1124",
                                    "@last": "1130"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Blackwell",
                                        "ce:indexed-name": "Blackwell K.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Burstein",
                                        "ce:indexed-name": "Burstein H.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Storniolo",
                                        "ce:indexed-name": "Storniolo A.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130."
                    },
                    {
                        "ref-fulltext": "Gui, X., Li, H., Yan, Y., et al. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncol Lett, 20(6), 2020, 378.",
                        "@reference-instance-id": "OB2BibRecID-948125942-4c3aae2c4ebc606bade7c948320579cb-91",
                        "@id": "91",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib91",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85095876514",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "6"
                                },
                                "pagerange": {"@first": "378"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Gui",
                                        "ce:indexed-name": "Gui X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncol Lett"
                        },
                        "ce:source-text": "Gui X, Li H, Yan Y, et al. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncol Lett. 2020;20(6):378."
                    },
                    {
                        "ref-fulltext": "Sudeep, G., Sanjoy, C., Jagdish, N., et al. Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: an Indian perspective. Indian J Med Paediatr Oncol 39:3 (2018), 368\u2013379.",
                        "@reference-instance-id": "OB2BibRecID-948125942-6f85b97d322a3626d63ac5683cb4960d-92",
                        "@id": "92",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: an Indian perspective"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib92",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051852169",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "39",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "368",
                                    "@last": "379"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Sudeep",
                                        "ce:indexed-name": "Sudeep G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Sanjoy",
                                        "ce:indexed-name": "Sanjoy C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Jagdish",
                                        "ce:indexed-name": "Jagdish N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Indian J Med Paediatr Oncol"
                        },
                        "ce:source-text": "Sudeep G, Sanjoy C, Jagdish N, et al. Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: an Indian perspective. Indian J Med Paediatr Oncol. 2018;39(3):368-379."
                    },
                    {
                        "ref-fulltext": "Ro, J., Park, S., Kim, S., et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer, 12, 2012, 322.",
                        "@reference-instance-id": "OB2BibRecID-948125942-4ab07f234f7b09c839745803d812942a-93",
                        "@id": "93",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib93",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84864191059",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {"@first": "322"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ro",
                                        "ce:indexed-name": "Ro J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMC Cancer"
                        },
                        "ce:source-text": "Ro J, Park S, Kim S, et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer. 2012;12:322."
                    },
                    {
                        "ref-fulltext": "Xu, B.H., Jiang, Z.F., Chua, D., et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30:5 (2011), 327\u2013335.",
                        "@reference-instance-id": "OB2BibRecID-948125942-715968f928851067081f6682eb81d74d-94",
                        "@id": "94",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib94",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79958157530",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "327",
                                    "@last": "335"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Jiang",
                                        "ce:indexed-name": "Jiang Z.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Chua",
                                        "ce:indexed-name": "Chua D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Chin J Cancer"
                        },
                        "ce:source-text": "Xu BH, Jiang ZF, Chua D, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer. 2011;30(5):327-335."
                    },
                    {
                        "ref-fulltext": "Saura, C., Oliveira, M., Feng, Y.H., et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 38:27 (2020), 3138\u20133149.",
                        "@reference-instance-id": "OB2BibRecID-948125942-e5c375fa7870c19ff5a6cfc67bbf3b97-95",
                        "@id": "95",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib95",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088803559",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "27"
                                },
                                "pagerange": {
                                    "@first": "3138",
                                    "@last": "3149"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Saura",
                                        "ce:indexed-name": "Saura C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Oliveira",
                                        "ce:indexed-name": "Oliveira M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Feng",
                                        "ce:indexed-name": "Feng Y.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138-3149."
                    },
                    {
                        "ref-fulltext": "Rugo, H.S., Im, S.A., Cardoso, F., et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 7:4 (2021), 573\u2013584.",
                        "@reference-instance-id": "OB2BibRecID-948125942-fd26e983fecb19c58f628cd4bee2c221-96",
                        "@id": "96",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib96",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85099823030",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "573",
                                    "@last": "584"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Cardoso",
                                        "ce:indexed-name": "Cardoso F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573-584."
                    },
                    {
                        "ref-fulltext": "Sim, S.H., Kim, J.E., Kim, M.H., et al. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B). Breast 65 (2022), 172\u2013178.",
                        "@reference-instance-id": "OB2BibRecID-948125942-8e559cf6ad0d193c4a47ed06a6aca253-97",
                        "@id": "97",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib97",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136302494",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "65"},
                                "pagerange": {
                                    "@first": "172",
                                    "@last": "178"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Sim",
                                        "ce:indexed-name": "Sim S.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim J.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim M.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast"
                        },
                        "ce:source-text": "Sim SH, Kim JE, Kim MH, et al. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B). Breast. 2022;65:172-178."
                    },
                    {
                        "ref-fulltext": "Lehmann, B.D., Pietenpol, J.A., Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:2 (2014), 142\u2013150.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d7898bcd31c5749c1f74834210860b32-98",
                        "@id": "98",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib98",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84890283025",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "232",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "142",
                                    "@last": "150"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Lehmann",
                                    "ce:indexed-name": "Lehmann B.D."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Pietenpol",
                                    "ce:indexed-name": "Pietenpol J.A."
                                }
                            ]},
                            "ref-sourcetitle": "J Pathol"
                        },
                        "ce:source-text": "Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142-150."
                    },
                    {
                        "ref-fulltext": "Yin, L., Duan, J.J., Bian, X.W., et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 22(1), 2020, 61.",
                        "@reference-instance-id": "OB2BibRecID-948125942-8de4621faca23c8a89d0c9600c73d41b-99",
                        "@id": "99",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Triple-negative breast cancer molecular subtyping and treatment progress"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib99",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086355994",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "61"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Yin",
                                        "ce:indexed-name": "Yin L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Duan",
                                        "ce:indexed-name": "Duan J.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Bian",
                                        "ce:indexed-name": "Bian X.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res"
                        },
                        "ce:source-text": "Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61."
                    },
                    {
                        "ref-fulltext": "Lee, J.A., Kim, K.I., Bae, J.W., et al. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123:1 (2010), 177\u2013187.",
                        "@reference-instance-id": "OB2BibRecID-948125942-999600af107e93723c026fb8797e64f9-100",
                        "@id": "100",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib100",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77955770298",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "123",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "177",
                                    "@last": "187"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim K.I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Bae",
                                        "ce:indexed-name": "Bae J.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Breast Cancer Res Treat"
                        },
                        "ce:source-text": "Lee JA, Kim KI, Bae JW, et al. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat. 2010;123(1):177-187."
                    },
                    {
                        "ref-fulltext": "Wang, C., Kar, S., Lai, X., et al. Triple negative breast cancer in Asia: an insider's view. Cancer Treat Rev 62 (2018), 29\u201338.",
                        "@reference-instance-id": "OB2BibRecID-948125942-f9921ae2bb15e33be6022f3b080a2f93-101",
                        "@id": "101",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Triple negative breast cancer in Asia: an insider's view"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib101",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85038871403",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "62"},
                                "pagerange": {
                                    "@first": "29",
                                    "@last": "38"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kar",
                                        "ce:indexed-name": "Kar S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Lai",
                                        "ce:indexed-name": "Lai X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Treat Rev"
                        },
                        "ce:source-text": "Wang C, Kar S, Lai X, et al. Triple negative breast cancer in Asia: an insider's view. Cancer Treat Rev. 2018;62:29-38."
                    },
                    {
                        "ref-fulltext": "Miles, D., Gligorov, J., Andre, F., et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:8 (2021), 994\u20131004.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d3bd757e4757df0164bf2350881cf442-102",
                        "@id": "102",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib102",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111080655",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "994",
                                    "@last": "1004"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Miles",
                                        "ce:indexed-name": "Miles D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gligorov",
                                        "ce:indexed-name": "Gligorov J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Andre",
                                        "ce:indexed-name": "Andre F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Miles D, Gligorov J, Andre F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994-1004."
                    },
                    {
                        "ref-fulltext": "Cortés, J., Cescon, D.W., Rugo, H.S., et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:10265 (2020), 1817\u20131828.",
                        "@reference-instance-id": "OB2BibRecID-948125942-7c7c295fa2bd896c98a220a6914fae4f-103",
                        "@id": "103",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib103",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097177716",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "396",
                                    "@issue": "10265"
                                },
                                "pagerange": {
                                    "@first": "1817",
                                    "@last": "1828"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Cortés",
                                        "ce:indexed-name": "Cortes J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Cescon",
                                        "ce:indexed-name": "Cescon D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828."
                    },
                    {
                        "ref-fulltext": "Im, S.A., Xu, B., Li, W., et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Sci Rep, 10(1), 2020, 8753.",
                        "@reference-instance-id": "OB2BibRecID-948125942-f4e68790fda23a6e82697c03e1b8e6a7-104",
                        "@id": "104",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib104",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85085715184",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "8753"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Im SA, Xu B, Li W, et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Sci Rep. 2020;10(1):8753."
                    },
                    {
                        "ref-fulltext": "Lee, K.H., Sohn, J., Goodwin, A., et al. Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial. Cancer Res Treat 53:4 (2021), 1084\u20131095.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a5e265f109681938aa1623411e88961d-105",
                        "@id": "105",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib105",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111600834",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "53",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "1084",
                                    "@last": "1095"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee K.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Sohn",
                                        "ce:indexed-name": "Sohn J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goodwin",
                                        "ce:indexed-name": "Goodwin A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Res Treat"
                        },
                        "ce:source-text": "Lee KH, Sohn J, Goodwin A, et al. Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial. Cancer Res Treat. 2021;53(4):1084-1095."
                    },
                    {
                        "ref-fulltext": "Tutt, A., Tovey, H., Cheang, M.C.U., et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 24:5 (2018), 628\u2013637.",
                        "@reference-instance-id": "OB2BibRecID-948125942-6f63b8fab20ad918b8494d359c6fc8cb-106",
                        "@id": "106",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib106",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85046110400",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "628",
                                    "@last": "637"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Tutt",
                                        "ce:indexed-name": "Tutt A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Tovey",
                                        "ce:indexed-name": "Tovey H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.C.U.",
                                        "@_fa": "true",
                                        "ce:surname": "Cheang",
                                        "ce:indexed-name": "Cheang M.C.U."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628-637."
                    },
                    {
                        "ref-fulltext": "Hu, X.C., Zhang, J., Xu, B.H., et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:4 (2015), 436\u2013446.",
                        "@reference-instance-id": "OB2BibRecID-948125942-953969f955e7eb110a55e08b760ed121-107",
                        "@id": "107",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib107",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84933500899",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "16",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "436",
                                    "@last": "446"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu X.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436-446."
                    },
                    {
                        "ref-fulltext": "Zhang, J., Wang, Z., Hu, X., et al. Cisplatin and gemcitabine as the first-line therapy in metastatic triple negative breast cancer. Int J Cancer 136:1 (2015), 204\u2013211.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1cecb479ced8a9ae12567b6416035686-108",
                        "@id": "108",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Cisplatin and gemcitabine as the first-line therapy in metastatic triple negative breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib108",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84925283516",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "136",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "204",
                                    "@last": "211"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Cancer"
                        },
                        "ce:source-text": "Zhang J, Wang Z, Hu X, et al. Cisplatin and gemcitabine as the first-line therapy in metastatic triple negative breast cancer. Int J Cancer. 2015;136(1):204-211."
                    },
                    {
                        "ref-fulltext": "Piccart-Gebhart, M.J., Burzykowski, T., Buyse, M., et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:12 (2008), 1980\u20131986.",
                        "@reference-instance-id": "OB2BibRecID-948125942-e357c1c8ea8be1cb3fed562d963fd380-109",
                        "@id": "109",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib109",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "42949158252",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1980",
                                    "@last": "1986"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Piccart-Gebhart",
                                        "ce:indexed-name": "Piccart-Gebhart M.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Burzykowski",
                                        "ce:indexed-name": "Burzykowski T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Buyse",
                                        "ce:indexed-name": "Buyse M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980-1986."
                    },
                    {
                        "ref-fulltext": "Yardley, D.A., Coleman, R., Conte, P., et al. Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 29:8 (2018), 1763\u20131770.",
                        "@reference-instance-id": "OB2BibRecID-948125942-9cef173f511396bec7b9f602441c0a42-110",
                        "@id": "110",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib110",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85055535644",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "1763",
                                    "@last": "1770"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Yardley",
                                        "ce:indexed-name": "Yardley D.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Coleman",
                                        "ce:indexed-name": "Coleman R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Conte",
                                        "ce:indexed-name": "Conte P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Yardley DA, Coleman R, Conte P, et al. Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018;29(8):1763-1770."
                    },
                    {
                        "ref-fulltext": "Bardia, A., Hurvitz, S.A., Tolaney, S.M., et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:16 (2021), 1529\u20131541.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a87c10756a07f8a26981d57821778c41-111",
                        "@id": "111",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Sacituzumab govitecan in metastatic triple-negative breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib111",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85104884390",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "384",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "1529",
                                    "@last": "1541"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hurvitz",
                                        "ce:indexed-name": "Hurvitz S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Tolaney",
                                        "ce:indexed-name": "Tolaney S.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541."
                    },
                    {
                        "ref-fulltext": "Bardia, A., Messersmith, W.A., Kio, E.A., et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol 32:6 (2021), 746\u2013756.",
                        "@reference-instance-id": "OB2BibRecID-948125942-fac98dadfbddd8ab4ddb708f77e2c112-112",
                        "@id": "112",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib112",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85104855700",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "746",
                                    "@last": "756"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Messersmith",
                                        "ce:indexed-name": "Messersmith W.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kio",
                                        "ce:indexed-name": "Kio E.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746-756."
                    },
                    {
                        "ref-fulltext": "Modi, S., Park, H., Murthy, R.K., et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38:17 (2020), 1887\u20131896.",
                        "@reference-instance-id": "OB2BibRecID-948125942-a376b1787ecaa05a128cb1c35cb4af34-113",
                        "@id": "113",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib113",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85081268424",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1887",
                                    "@last": "1896"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Murthy",
                                        "ce:indexed-name": "Murthy R.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38(17):1887-1896."
                    },
                    {
                        "ref-fulltext": "Modi, S., Saura, C., Yamashita, T., et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:7 (2020), 610\u2013621.",
                        "@reference-instance-id": "OB2BibRecID-948125942-893a50dd4259ec5aa0f7b99b6b486085-114",
                        "@id": "114",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Trastuzumab deruxtecan in previously treated HER2-positive breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib114",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077471546",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "382",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "610",
                                    "@last": "621"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Modi",
                                        "ce:indexed-name": "Modi S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Saura",
                                        "ce:indexed-name": "Saura C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamashita",
                                        "ce:indexed-name": "Yamashita T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621."
                    },
                    {
                        "ref-fulltext": "Robson, M., Ruddy, K.J., Im, S.A., et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 120 (2019), 20\u201330.",
                        "@reference-instance-id": "OB2BibRecID-948125942-1703402f0e2b03d147045b4b9189a5f0-115",
                        "@id": "115",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib115",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85070926015",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "120"},
                                "pagerange": {
                                    "@first": "20",
                                    "@last": "30"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Robson",
                                        "ce:indexed-name": "Robson M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruddy",
                                        "ce:indexed-name": "Ruddy K.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Im",
                                        "ce:indexed-name": "Im S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Robson M, Ruddy KJ, Im SA, et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer. 2019;120:20-30."
                    },
                    {
                        "ref-fulltext": "Badwe, R., Hawaldar, R., Nair, N., et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16:13 (2015), 1380\u20131388.",
                        "@reference-instance-id": "OB2BibRecID-948125942-875717cf54d0ec6205e7296f110cb8c8-116",
                        "@id": "116",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib116",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84952871468",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "16",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "1380",
                                    "@last": "1388"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Badwe",
                                        "ce:indexed-name": "Badwe R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Hawaldar",
                                        "ce:indexed-name": "Hawaldar R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Nair",
                                        "ce:indexed-name": "Nair N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380-1388."
                    },
                    {
                        "ref-fulltext": "Fitzal, F., Bjelic-Radisic, V., Knauer, M., et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg 269:6 (2019), 1163\u20131169.",
                        "@reference-instance-id": "OB2BibRecID-948125942-8b32be5e1840bbbcc44c4b15024158c6-117",
                        "@id": "117",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib117",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066060786",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "269",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1163",
                                    "@last": "1169"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Fitzal",
                                        "ce:indexed-name": "Fitzal F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Bjelic-Radisic",
                                        "ce:indexed-name": "Bjelic-Radisic V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Knauer",
                                        "ce:indexed-name": "Knauer M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Surg"
                        },
                        "ce:source-text": "Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269(6):1163-1169."
                    },
                    {
                        "ref-fulltext": "Soran, A., Ozmen, V., Ozbas, S., et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol 25:11 (2018), 3141\u20133149.",
                        "@reference-instance-id": "OB2BibRecID-948125942-df3c40352db3b333279a8e503066b09f-118",
                        "@id": "118",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib118",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047165280",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "3141",
                                    "@last": "3149"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Soran",
                                        "ce:indexed-name": "Soran A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Ozmen",
                                        "ce:indexed-name": "Ozmen V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ozbas",
                                        "ce:indexed-name": "Ozbas S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Surg Oncol"
                        },
                        "ce:source-text": "Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141-3149."
                    },
                    {
                        "ref-fulltext": "Khan, S.A., Zhao, F., Solin, L.J., et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (2108). J Clin Oncol, 38, 2020 LBA2.",
                        "@reference-instance-id": "OB2BibRecID-948125942-224b9b8f7bb13a51a00504563d2d3c6c-119",
                        "@id": "119",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (2108)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib119",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088437950",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "38"}},
                            "ref-text": "LBA2",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Khan",
                                        "ce:indexed-name": "Khan S.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhao",
                                        "ce:indexed-name": "Zhao F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Solin",
                                        "ce:indexed-name": "Solin L.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (2108). J Clin Oncol. 2020;38:LBA2."
                    },
                    {
                        "ref-fulltext": "Le Rhun, E., Guckenberger, M., Smits, M., et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32:11 (2021), 1332\u20131347.",
                        "@reference-instance-id": "OB2BibRecID-948125942-3add44beca3025c357fc1f028973f16e-120",
                        "@id": "120",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib120",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85114662933",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1332",
                                    "@last": "1347"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Le Rhun",
                                        "ce:indexed-name": "Le Rhun E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Guckenberger",
                                        "ce:indexed-name": "Guckenberger M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Smits",
                                        "ce:indexed-name": "Smits M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332-1347."
                    },
                    {
                        "ref-fulltext": "Harbeck, N., Franke, F., Villanueva-Vazquez, R., et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol, 12, 2020, 1758835920943065.",
                        "@reference-instance-id": "OB2BibRecID-948125942-d1444c0ba563e6e60d44ce1ac854409a-121",
                        "@id": "121",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib121",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "1758835920943065",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85088639533",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "12"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Harbeck",
                                        "ce:indexed-name": "Harbeck N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Franke",
                                        "ce:indexed-name": "Franke F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Villanueva-Vazquez",
                                        "ce:indexed-name": "Villanueva-Vazquez R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ther Adv Med Oncol"
                        },
                        "ce:source-text": "Harbeck N, Franke F, Villanueva-Vazquez R, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065."
                    },
                    {
                        "ref-fulltext": "Ciruelos, E.M., Rugo, H.S., Mayer, I.A., et al. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1. J Clin Oncol 39:18 (2021), 2005\u20132015.",
                        "@reference-instance-id": "OB2BibRecID-948125942-0d9c055a39c4e67811775487d816ce1a-122",
                        "@id": "122",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib122",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85108386804",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "39",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "2005",
                                    "@last": "2015"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ciruelos",
                                        "ce:indexed-name": "Ciruelos E.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rugo",
                                        "ce:indexed-name": "Rugo H.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mayer",
                                        "ce:indexed-name": "Mayer I.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Ciruelos EM, Rugo HS, Mayer IA, et al. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1. J Clin Oncol. 2021;39(18):2005-2015."
                    },
                    {
                        "ref-fulltext": "Murthy, R., Borges, V.F., Conlin, A., et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:7 (2018), 880\u2013888.",
                        "@reference-instance-id": "OB2BibRecID-948125942-8e0cd49b63ec147e76c510ac76a77a1d-123",
                        "@id": "123",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib123",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85047241419",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "880",
                                    "@last": "888"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Murthy",
                                        "ce:indexed-name": "Murthy R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Borges",
                                        "ce:indexed-name": "Borges V.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Conlin",
                                        "ce:indexed-name": "Conlin A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880-888."
                    },
                    {
                        "ref-fulltext": "Litton, J.K., Hurvitz, S.A., Mina, L.A., et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31:11 (2020), 1526\u20131535.",
                        "@reference-instance-id": "OB2BibRecID-948125942-cb2bab1e1767e44add16269b83be68e2-124",
                        "@id": "124",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib124",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85092215405",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1526",
                                    "@last": "1535"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Litton",
                                        "ce:indexed-name": "Litton J.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hurvitz",
                                        "ce:indexed-name": "Hurvitz S.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mina",
                                        "ce:indexed-name": "Mina L.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535."
                    },
                    {
                        "ref-fulltext": "Bardia, A., Tolaney, S.M., Punie, K., et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 32:9 (2021), 1148\u20131156.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5d374313714cdd8bb274491ee4e431e6-125",
                        "@id": "125",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib125",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85109025820",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1148",
                                    "@last": "1156"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bardia",
                                        "ce:indexed-name": "Bardia A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Tolaney",
                                        "ce:indexed-name": "Tolaney S.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Punie",
                                        "ce:indexed-name": "Punie K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148-1156."
                    },
                    {
                        "ref-fulltext": "Ma, F., Ouyang, Q., Li, W., et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol 37:29 (2019), 2610\u20132619.",
                        "@reference-instance-id": "OB2BibRecID-948125942-48a95d53699d2b12fba5a284133bc104-126",
                        "@id": "126",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib126",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072993966",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "37",
                                    "@issue": "29"
                                },
                                "pagerange": {
                                    "@first": "2610",
                                    "@last": "2619"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Ouyang",
                                        "ce:indexed-name": "Ouyang Q."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37(29):2610-2619."
                    },
                    {
                        "ref-fulltext": "Anwar, M., Chen, Q., Ouyang, D., et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data. Clin Cancer Res 27:16 (2021), 4634\u20134641.",
                        "@reference-instance-id": "OB2BibRecID-948125942-97f8524368e33b8229e5332a542a3f07-127",
                        "@id": "127",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib127",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85113633827",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "4634",
                                    "@last": "4641"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Anwar",
                                        "ce:indexed-name": "Anwar M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen Q."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Ouyang",
                                        "ce:indexed-name": "Ouyang D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Anwar M, Chen Q, Ouyang D, et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data. Clin Cancer Res. 2021;27(16):4634-4641."
                    },
                    {
                        "ref-fulltext": "Zhang, L., Wu, X., Zhou, J., et al. Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, real-world study. Front Oncol, 11, 2021, 699323.",
                        "@reference-instance-id": "OB2BibRecID-948125942-000332bab8f3be2e34b67e1d21e61957-128",
                        "@id": "128",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, real-world study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib128",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "699323",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85111593559",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "11"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Oncol"
                        },
                        "ce:source-text": "Zhang L, Wu X, Zhou J, et al. Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, real-world study. Front Oncol. 2021;11:699323."
                    },
                    {
                        "ref-fulltext": "Xu, B., Yan, M., Ma, F., et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22:3 (2021), 351\u2013360.",
                        "@reference-instance-id": "OB2BibRecID-948125942-41eb149305d8580ae151d40aa7b4730f-129",
                        "@id": "129",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib129",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101699848",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "351",
                                    "@last": "360"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351-360."
                    },
                    {
                        "ref-fulltext": "Xu, B., Yan, M., Ma, F., et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase III trial. Ann Oncol, 33, 2022, LBA19.",
                        "@reference-instance-id": "OB2BibRecID-948125942-aeaeb8a26ee9b438ef205e9d305a0d75-130",
                        "@id": "130",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase III trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib130",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85165518761",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "33"},
                                "pagerange": {"@first": "LBA19"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Xu B, Yan M, Ma F, et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase III trial. Ann Oncol. 2022;33:LBA19."
                    },
                    {
                        "ref-fulltext": "Xu, B., Zhang, Q., Zhang, P., et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 27:11 (2021), 1904\u20131909.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5ceb7f928fcb9989e4b95ef196f208e9-131",
                        "@id": "131",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib131",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85118888923",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1904",
                                    "@last": "1909"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang Q."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27(11):1904-1909."
                    },
                    {
                        "ref-fulltext": "Zhang, J., Meng, Y., Wang, B., et al. Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase Ib study. Front Oncol, 12, 2022, 775081.",
                        "@reference-instance-id": "OB2BibRecID-948125942-9052619ab2fd7ebfd3a19d635fcba396-132",
                        "@id": "132",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase Ib study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib132",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "775081",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85127377186",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "12"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Meng",
                                        "ce:indexed-name": "Meng Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Oncol"
                        },
                        "ce:source-text": "Zhang J, Meng Y, Wang B, et al. Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase Ib study. Front Oncol. 2022;12:775081."
                    },
                    {
                        "ref-fulltext": "Mateo, J., Chakravarty, D., Dienstmann, R., et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29:9 (2018), 1895\u20131902.",
                        "@reference-instance-id": "OB2BibRecID-948125942-5ebcca7b77ac3f7aa02f4b4b38ed0ab5-133",
                        "@id": "133",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib133",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85054325308",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1895",
                                    "@last": "1902"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Mateo",
                                        "ce:indexed-name": "Mateo J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Chakravarty",
                                        "ce:indexed-name": "Chakravarty D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Dienstmann",
                                        "ce:indexed-name": "Dienstmann R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895-1902."
                    },
                    {
                        "ref-fulltext": "Cherny, N.I., Dafni, U., Bogaerts, J., et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 28:10 (2017), 2340\u20132366.",
                        "@reference-instance-id": "OB2BibRecID-948125942-39384678e9e482edbc12cf1e34d52583-134",
                        "@id": "134",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "ESMO-Magnitude of Clinical Benefit Scale version 1.1"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib134",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85030556510",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2340",
                                    "@last": "2366"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Cherny",
                                        "ce:indexed-name": "Cherny N.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Dafni",
                                        "ce:indexed-name": "Dafni U."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bogaerts",
                                        "ce:indexed-name": "Bogaerts J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340-2366."
                    },
                    {
                        "ref-fulltext": "Li, C., Bian, X., Liu, Z., et al. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a real-world retrospective study. Cancer Med 10:23 (2021), 8352\u20138364.",
                        "@reference-instance-id": "OB2BibRecID-948125942-70159f4dc0275d6f4624e82a3f6cb2dc-135",
                        "@id": "135",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a real-world retrospective study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib135",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85117407241",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "8352",
                                    "@last": "8364"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Bian",
                                        "ce:indexed-name": "Bian X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu Z."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Med"
                        },
                        "ce:source-text": "Li C, Bian X, Liu Z, et al. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a real-world retrospective study. Cancer Med. 2021;10(23):8352-8364."
                    },
                    {
                        "ref-fulltext": "Li, F., Xu, F., Li, J., et al. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Ann Transl Med, 9(2), 2021, 103.",
                        "@reference-instance-id": "OB2BibRecID-948125942-82bd51185112905fd91be7b763509a04-136",
                        "@id": "136",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib136",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85106041615",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "9",
                                    "@issue": "2"
                                },
                                "pagerange": {"@first": "103"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Transl Med"
                        },
                        "ce:source-text": "Li F, Xu F, Li J, et al. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Ann Transl Med. 2021;9(2):103."
                    },
                    {
                        "ref-fulltext": "Ma, X., Li, Y., Li, L., et al. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases. Ann Med 54:1 (2022), 3085\u20133095.",
                        "@reference-instance-id": "OB2BibRecID-948125942-e10274a6597d1d23078987a0db69d8ef-137",
                        "@id": "137",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib137",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85141678727",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "54",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "3085",
                                    "@last": "3095"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Ma",
                                        "ce:indexed-name": "Ma X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Med"
                        },
                        "ce:source-text": "Ma X, Li Y, Li L, et al. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases. Ann Med. 2022;54(1):3085-3095."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60010400",
            "affilname": "Pantai Holdings Sdn Bhd",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010400",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60068691",
            "affilname": "Asan Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Kashiwa",
            "@id": "60010925",
            "affilname": "National Cancer Center Hospital East",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010925",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Seongnam",
            "@id": "60199632",
            "affilname": "Gachon University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199632",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "West Jakarta",
            "@id": "60196808",
            "affilname": "Rumah Sakit Kanker Dharmais",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60196808",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Izumo",
            "@id": "60160813",
            "affilname": "Shimane University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60160813",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60119956",
            "affilname": "Seoul National University Cancer Research Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60119956",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seongnam",
            "@id": "60098516",
            "affilname": "Seoul National University Bundang Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60098516",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Mumbai",
            "@id": "60079949",
            "affilname": "Homi Bhabha National Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60079949",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "@id": "60071489",
            "affilname": "University of Santo Tomas Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071489",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Quezon City",
            "@id": "60071484",
            "affilname": "St. Luke's Medical Center Quezon City",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071484",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60069744",
            "affilname": "General Hospital of People's Liberation Army",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069744",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60069716",
            "affilname": "National Yang-Ming University Taiwan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069716",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bandung",
            "@id": "60069388",
            "affilname": "Universitas Padjadjaran",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069388",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60030442",
            "affilname": "Istituto Europeo di Oncologia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030442",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60030318",
            "affilname": "Università degli Studi di Milano",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030318",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Lausanne",
            "@id": "60023561",
            "affilname": "Centre Hospitalier Universitaire Vaudois",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023561",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60021182",
            "affilname": "Sun Yat-Sen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021182",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60020857",
            "affilname": "Samsung Medical Center, Sungkyunkwan university",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020857",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60013314",
            "affilname": "Veterans General Hospital-Taipei",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Mumbai",
            "@id": "60011172",
            "affilname": "Bombay Hospital and Medical Research Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011172",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Vercelli",
            "@id": "60003668",
            "affilname": "Università degli Studi del Piemonte Orientale \"Amedeo Avogadro\"",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003668",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Munich",
            "@id": "60000291",
            "affilname": "Klinikum der Universität München",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "127780700",
            "affilname": "National University Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127780700",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Lugano",
            "@id": "119221731",
            "affilname": "ESMO",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/119221731",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "San Juan",
            "@id": "100624745",
            "affilname": "Cardinal Santos Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100624745",
            "affiliation-country": "Philippines"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85159041839",
        "dc:description": "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.",
        "pubmed-id": "37178669",
        "prism:coverDate": "2023-06-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85159041839",
        "dc:creator": {"author": [{
            "preferred-name": {
                "ce:given-name": "S. A.",
                "ce:initials": "S.A.",
                "ce:surname": "Im",
                "ce:indexed-name": "Im S.A."
            },
            "@seq": "1",
            "ce:initials": "S.-A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60119956",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60119956"
            },
            "ce:surname": "Im",
            "@auid": "34570185300",
            "author-url": "https://api.elsevier.com/content/author/author_id/34570185300",
            "ce:indexed-name": "Im S.-A."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85159041839"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85159041839&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85159041839&origin=inward"
            }
        ],
        "source-id": "21100873339",
        "pii": "S2059702923007676",
        "citedby-count": "1",
        "prism:volume": "8",
        "subtype": "ar",
        "dc:title": "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer",
        "openaccess": "1",
        "prism:issn": "20597029",
        "publishercopyright": "© 2023 The Authors",
        "article-number": "101541",
        "prism:issueIdentifier": "3",
        "subtypeDescription": "Article",
        "prism:publicationName": "ESMO Open",
        "openaccessFlag": "true",
        "prism:doi": "10.1016/j.esmoop.2023.101541",
        "dc:identifier": "SCOPUS_ID:85159041839",
        "dc:publisher": "Elsevier B.V."
    },
    "idxterms": {"mainterm": [
        {
            "$": "Asia",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Breast Neoplasms",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "India",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Medical Oncology",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Societies, Medical",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "ESMO"
        },
        {
            "@_fa": "true",
            "$": "guidelines"
        },
        {
            "@_fa": "true",
            "$": "metastatic breast cancer"
        },
        {
            "@_fa": "true",
            "$": "Pan-Asian"
        },
        {
            "@_fa": "true",
            "$": "treatment"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ]},
    "authors": {"author": [
        {
            "preferred-name": {
                "ce:given-name": "S. A.",
                "ce:initials": "S.A.",
                "ce:surname": "Im",
                "ce:indexed-name": "Im S.A."
            },
            "@seq": "1",
            "ce:initials": "S.-A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60119956",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60119956"
            },
            "ce:surname": "Im",
            "@auid": "34570185300",
            "author-url": "https://api.elsevier.com/content/author/author_id/34570185300",
            "ce:indexed-name": "Im S.-A."
        },
        {
            "preferred-name": {
                "ce:given-name": "A.",
                "ce:initials": "A.",
                "ce:surname": "Gennari",
                "ce:indexed-name": "Gennari A."
            },
            "@seq": "2",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60003668",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003668"
            },
            "ce:surname": "Gennari",
            "@auid": "7003822754",
            "author-url": "https://api.elsevier.com/content/author/author_id/7003822754",
            "ce:indexed-name": "Gennari A."
        },
        {
            "preferred-name": {
                "ce:given-name": "Y. H.",
                "ce:initials": "Y.H.",
                "ce:surname": "Park",
                "ce:indexed-name": "Park Y.H."
            },
            "@seq": "3",
            "ce:initials": "Y.H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60020857",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020857"
            },
            "ce:surname": "Park",
            "@auid": "35273175600",
            "author-url": "https://api.elsevier.com/content/author/author_id/35273175600",
            "ce:indexed-name": "Park Y.H."
        },
        {
            "preferred-name": {
                "ce:given-name": "J. H.",
                "ce:initials": "J.H.",
                "ce:surname": "Kim",
                "ce:indexed-name": "Kim J.H."
            },
            "@seq": "4",
            "ce:initials": "J.H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60098516",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60098516"
            },
            "ce:surname": "Kim",
            "@auid": "57221538586",
            "author-url": "https://api.elsevier.com/content/author/author_id/57221538586",
            "ce:indexed-name": "Kim J.H."
        },
        {
            "preferred-name": {
                "ce:given-name": "Z. F.",
                "ce:initials": "Z.F.",
                "ce:surname": "Jiang",
                "ce:indexed-name": "Jiang Z.F."
            },
            "@seq": "5",
            "ce:initials": "Z.-F.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60069744",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069744"
            },
            "ce:surname": "Jiang",
            "@auid": "57205353572",
            "author-url": "https://api.elsevier.com/content/author/author_id/57205353572",
            "ce:indexed-name": "Jiang Z.-F."
        },
        {
            "preferred-name": {
                "ce:given-name": "S.",
                "ce:initials": "S.",
                "ce:surname": "Gupta",
                "ce:indexed-name": "Gupta S."
            },
            "@seq": "6",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60079949",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60079949"
            },
            "ce:surname": "Gupta",
            "@auid": "57213338151",
            "author-url": "https://api.elsevier.com/content/author/author_id/57213338151",
            "ce:indexed-name": "Gupta S."
        },
        {
            "preferred-name": {
                "ce:given-name": "T. H.",
                "ce:initials": "T.H.",
                "ce:surname": "Fadjari",
                "ce:indexed-name": "Fadjari T.H."
            },
            "@seq": "7",
            "ce:initials": "T.H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60069388",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069388"
            },
            "ce:surname": "Fadjari",
            "@auid": "15055794000",
            "author-url": "https://api.elsevier.com/content/author/author_id/15055794000",
            "ce:indexed-name": "Fadjari T.H."
        },
        {
            "preferred-name": {
                "ce:given-name": "K.",
                "ce:initials": "K.",
                "ce:surname": "Tamura",
                "ce:indexed-name": "Tamura K."
            },
            "@seq": "8",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60160813",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60160813"
            },
            "ce:surname": "Tamura",
            "@auid": "58279482400",
            "author-url": "https://api.elsevier.com/content/author/author_id/58279482400",
            "ce:indexed-name": "Tamura K."
        },
        {
            "preferred-name": {
                "ce:given-name": "M. Y.",
                "ce:initials": "M.Y.",
                "ce:surname": "Mastura",
                "ce:indexed-name": "Mastura M.Y."
            },
            "@seq": "9",
            "ce:initials": "M.Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60010400",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010400"
            },
            "ce:surname": "Mastura",
            "@auid": "14060650200",
            "author-url": "https://api.elsevier.com/content/author/author_id/14060650200",
            "ce:indexed-name": "Mastura M.Y."
        },
        {
            "preferred-name": {
                "ce:given-name": "M. L.T.",
                "ce:initials": "M.L.T.",
                "ce:surname": "Abesamis-Tiambeng",
                "ce:indexed-name": "Abesamis-Tiambeng M.L.T."
            },
            "@seq": "10",
            "ce:initials": "M.L.T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100624745",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100624745"
            },
            "ce:surname": "Abesamis-Tiambeng",
            "@auid": "57192835193",
            "author-url": "https://api.elsevier.com/content/author/author_id/57192835193",
            "ce:indexed-name": "Abesamis-Tiambeng M.L.T."
        },
        {
            "preferred-name": {
                "ce:given-name": "E. H.",
                "ce:initials": "E.H.",
                "ce:surname": "Lim",
                "ce:indexed-name": "Lim E.H."
            },
            "@seq": "11",
            "ce:initials": "E.H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031809",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809"
            },
            "ce:surname": "Lim",
            "@auid": "57644559300",
            "author-url": "https://api.elsevier.com/content/author/author_id/57644559300",
            "ce:indexed-name": "Lim E.H."
        },
        {
            "preferred-name": {
                "ce:given-name": "C. H.",
                "ce:initials": "C.H.",
                "ce:surname": "Lin",
                "ce:indexed-name": "Lin C.H."
            },
            "@seq": "12",
            "ce:initials": "C.-H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60073385",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385"
            },
            "ce:surname": "Lin",
            "@auid": "23668134300",
            "author-url": "https://api.elsevier.com/content/author/author_id/23668134300",
            "ce:indexed-name": "Lin C.-H."
        },
        {
            "preferred-name": {
                "ce:given-name": "A.",
                "ce:initials": "A.",
                "ce:surname": "Sookprasert",
                "ce:indexed-name": "Sookprasert A."
            },
            "@seq": "13",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60026046",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046"
            },
            "ce:surname": "Sookprasert",
            "@auid": "26024452800",
            "author-url": "https://api.elsevier.com/content/author/author_id/26024452800",
            "ce:indexed-name": "Sookprasert A."
        },
        {
            "preferred-name": {
                "ce:given-name": "N.",
                "ce:initials": "N.",
                "ce:surname": "Parinyanitikul",
                "ce:indexed-name": "Parinyanitikul N."
            },
            "@seq": "14",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Parinyanitikul",
            "@auid": "36554719100",
            "author-url": "https://api.elsevier.com/content/author/author_id/36554719100",
            "ce:indexed-name": "Parinyanitikul N."
        },
        {
            "preferred-name": {
                "ce:given-name": "L. M.",
                "ce:initials": "L.M.",
                "ce:surname": "Tseng",
                "ce:indexed-name": "Tseng L.M."
            },
            "@seq": "15",
            "ce:initials": "L.-M.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60013314",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314"
                },
                {
                    "@id": "60069716",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069716"
                }
            ],
            "ce:surname": "Tseng",
            "@auid": "7201526690",
            "author-url": "https://api.elsevier.com/content/author/author_id/7201526690",
            "ce:indexed-name": "Tseng L.-M."
        },
        {
            "preferred-name": {
                "ce:given-name": "S. C.",
                "ce:initials": "S.C.",
                "ce:surname": "Lee",
                "ce:indexed-name": "Lee S.C."
            },
            "@seq": "16",
            "ce:initials": "S.-C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "127780700",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127780700"
            },
            "ce:surname": "Lee",
            "@auid": "56556623100",
            "author-url": "https://api.elsevier.com/content/author/author_id/56556623100",
            "ce:indexed-name": "Lee S.-C."
        },
        {
            "preferred-name": {
                "ce:given-name": "P.",
                "ce:initials": "P.",
                "ce:surname": "Caguioa",
                "ce:indexed-name": "Caguioa P."
            },
            "@seq": "17",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60071484",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071484"
                },
                {
                    "@id": "60071489",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071489"
                }
            ],
            "ce:surname": "Caguioa",
            "@auid": "6506598676",
            "author-url": "https://api.elsevier.com/content/author/author_id/6506598676",
            "ce:indexed-name": "Caguioa P."
        },
        {
            "preferred-name": {
                "ce:given-name": "M.",
                "ce:initials": "M.",
                "ce:surname": "Singh",
                "ce:indexed-name": "Singh M."
            },
            "@seq": "18",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60010400",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010400"
                },
                {
                    "@id": "60010400",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010400"
                }
            ],
            "ce:surname": "Singh",
            "@auid": "56591022100",
            "author-url": "https://api.elsevier.com/content/author/author_id/56591022100",
            "ce:indexed-name": "Singh M."
        },
        {
            "preferred-name": {
                "ce:given-name": "Y.",
                "ce:initials": "Y.",
                "ce:surname": "Naito",
                "ce:indexed-name": "Naito Y."
            },
            "@seq": "19",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60010925",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010925"
            },
            "ce:surname": "Naito",
            "@auid": "14025801500",
            "author-url": "https://api.elsevier.com/content/author/author_id/14025801500",
            "ce:indexed-name": "Naito Y."
        },
        {
            "preferred-name": {
                "ce:given-name": "R. A.",
                "ce:initials": "R.A.",
                "ce:surname": "Hukom",
                "ce:indexed-name": "Hukom R.A."
            },
            "@seq": "20",
            "ce:initials": "R.A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60196808",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60196808"
            },
            "ce:surname": "Hukom",
            "@auid": "8977682700",
            "author-url": "https://api.elsevier.com/content/author/author_id/8977682700",
            "ce:indexed-name": "Hukom R.A."
        },
        {
            "preferred-name": {
                "ce:given-name": "B. K.",
                "ce:initials": "B.K.",
                "ce:surname": "Smruti",
                "ce:indexed-name": "Smruti B.K."
            },
            "@seq": "21",
            "ce:initials": "B.K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60011172",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011172"
            },
            "ce:surname": "Smruti",
            "@auid": "6506962894",
            "author-url": "https://api.elsevier.com/content/author/author_id/6506962894",
            "ce:indexed-name": "Smruti B.K."
        },
        {
            "preferred-name": {
                "ce:given-name": "S. S.",
                "ce:initials": "S.S.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang S.S."
            },
            "@seq": "22",
            "ce:initials": "S.-S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60021182",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021182"
            },
            "ce:surname": "Wang",
            "@auid": "57852636600",
            "author-url": "https://api.elsevier.com/content/author/author_id/57852636600",
            "ce:indexed-name": "Wang S.-S."
        },
        {
            "preferred-name": {
                "ce:given-name": "S. B.",
                "ce:initials": "S.B.",
                "ce:surname": "Kim",
                "ce:indexed-name": "Kim S.B."
            },
            "@seq": "23",
            "ce:initials": "S.B.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60068691",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691"
            },
            "ce:surname": "Kim",
            "@auid": "34770722200",
            "author-url": "https://api.elsevier.com/content/author/author_id/34770722200",
            "ce:indexed-name": "Kim S.B."
        },
        {
            "preferred-name": {
                "ce:given-name": "K. H.",
                "ce:initials": "K.H.",
                "ce:surname": "Lee",
                "ce:indexed-name": "Lee K.H."
            },
            "@seq": "24",
            "ce:initials": "K.-H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60119956",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60119956"
            },
            "ce:surname": "Lee",
            "@auid": "55549466700",
            "author-url": "https://api.elsevier.com/content/author/author_id/55549466700",
            "ce:indexed-name": "Lee K.-H."
        },
        {
            "preferred-name": {
                "ce:given-name": "H. K.",
                "ce:initials": "H.K.",
                "ce:surname": "Ahn",
                "ce:indexed-name": "Ahn H.K."
            },
            "@seq": "25",
            "ce:initials": "H.K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60199632",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199632"
            },
            "ce:surname": "Ahn",
            "@auid": "50261094700",
            "author-url": "https://api.elsevier.com/content/author/author_id/50261094700",
            "ce:indexed-name": "Ahn H.K."
        },
        {
            "preferred-name": {
                "ce:given-name": "S.",
                "ce:initials": "S.",
                "ce:surname": "Peters",
                "ce:indexed-name": "Peters S."
            },
            "@seq": "26",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60023561",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023561"
            },
            "ce:surname": "Peters",
            "@auid": "57218315686",
            "author-url": "https://api.elsevier.com/content/author/author_id/57218315686",
            "ce:indexed-name": "Peters S."
        },
        {
            "preferred-name": {
                "ce:given-name": "T. W.",
                "ce:initials": "T.W.",
                "ce:surname": "Kim",
                "ce:indexed-name": "Kim T.W."
            },
            "@seq": "27",
            "ce:initials": "T.W.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60068691",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691"
            },
            "ce:surname": "Kim",
            "@auid": "56504151300",
            "author-url": "https://api.elsevier.com/content/author/author_id/56504151300",
            "ce:indexed-name": "Kim T.W."
        },
        {
            "preferred-name": {
                "ce:given-name": "T.",
                "ce:initials": "T.",
                "ce:surname": "Yoshino",
                "ce:indexed-name": "Yoshino T."
            },
            "@seq": "28",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60010925",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010925"
            },
            "ce:surname": "Yoshino",
            "@auid": "57205400013",
            "author-url": "https://api.elsevier.com/content/author/author_id/57205400013",
            "ce:indexed-name": "Yoshino T."
        },
        {
            "preferred-name": {
                "ce:given-name": "G.",
                "ce:initials": "G.",
                "ce:surname": "Pentheroudakis",
                "ce:indexed-name": "Pentheroudakis G."
            },
            "@seq": "29",
            "ce:initials": "G.",
            "@_fa": "true",
            "affiliation": {
                "@id": "119221731",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/119221731"
            },
            "ce:surname": "Pentheroudakis",
            "@auid": "56230606500",
            "author-url": "https://api.elsevier.com/content/author/author_id/56230606500",
            "ce:indexed-name": "Pentheroudakis G."
        },
        {
            "preferred-name": {
                "ce:given-name": "G.",
                "ce:initials": "G.",
                "ce:surname": "Curigliano",
                "ce:indexed-name": "Curigliano G."
            },
            "@seq": "30",
            "ce:initials": "G.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60030442",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030442"
                },
                {
                    "@id": "60030318",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030318"
                }
            ],
            "ce:surname": "Curigliano",
            "@auid": "57221578995",
            "author-url": "https://api.elsevier.com/content/author/author_id/57221578995",
            "ce:indexed-name": "Curigliano G."
        },
        {
            "preferred-name": {
                "ce:given-name": "N.",
                "ce:initials": "N.",
                "ce:surname": "Harbeck",
                "ce:indexed-name": "Harbeck N."
            },
            "@seq": "31",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60000291",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291"
            },
            "ce:surname": "Harbeck",
            "@auid": "34570179900",
            "author-url": "https://api.elsevier.com/content/author/author_id/34570179900",
            "ce:indexed-name": "Harbeck N."
        }
    ]}
}}